var title_f22_41_23184="Parasternal long axis normal";
var content_f22_41_23184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/79601/Parast_long_axis_norm_movie.mp4?title=Parasternal+long+axis+normal\" style=\"width:496px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Parasternal long view of normal cardiac function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip shows normal cardiac motion seen from a parasternal long axis view.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23184=[""].join("\n");
var outline_f22_41_23184=null;
var title_f22_41_23185="Basophils in CML";
var content_f22_41_23185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Basophils in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with newly diagnosed chronic myeloid leukemia, showing three normal-appearing basophils. These cells differ from a neutrophil by the presence of coarse, dark blue-black granules. (Wright-Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23185=[""].join("\n");
var outline_f22_41_23185=null;
var title_f22_41_23186="Infant oral health problems";
var content_f22_41_23186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infant oral health problems",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. Normal 12- to 14-month-old infant's mouth. B. Infant's mouth with plaque. C. Decalcification and early cavitation. D. Remineralized decalcified enamel. E. Hypoplastic enamel (no decay). F. Fractured primary teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nowak AJ, Warren JJ. Infant Oral Health and Oral Habits. Pediatr Clin North Am 2000; 47:1043. Copyright &copy; 2000 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23186=[""].join("\n");
var outline_f22_41_23186=null;
var title_f22_41_23187="Fundus after CRAO";
var content_f22_41_23187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fundus after CRAO",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus appearance of a complete central retinal artery occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23187=[""].join("\n");
var outline_f22_41_23187=null;
var title_f22_41_23188="Suspicious calcifications";
var content_f22_41_23188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Suspicious calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clustered microcalcifications in three different cases. A loose group of varying sizes of calcifications are seen in Panel A. A small cluster of powdery calcifications are seen in a background of dense breast parenchyma in Panel B. Very faint microcalcifications are seen in between coarse larger calcifications in Panel C.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23188=[""].join("\n");
var outline_f22_41_23188=null;
var title_f22_41_23189="Urothelial CIS E";
var content_f22_41_23189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23189=[""].join("\n");
var outline_f22_41_23189=null;
var title_f22_41_23190="Clinical features and management of foot pain in the young athlete";
var content_f22_41_23190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and management of foot pain in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Christopher R Powers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23190/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/41/23190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of musculoskeletal complaints are related to the foot and ankle, which is not surprising when one considers the functions of the foot:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It provides a stable base on which the body can stand.",
"     </li>",
"     <li>",
"      It acts as a rigid lever to propel the body forward during walking.",
"     </li>",
"     <li>",
"      It provides shock absorption for the force generated during walking and running (approximately two to six times an individual's body weight).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Foot pain in the young athlete can originate in the bones (fractures), ligaments (sprains), muscles and tendons, or fascia. Careful localization of the pain can help to narrow the differential diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=see_link\">",
"     \"Evaluation of foot and ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and management of foot pain, other than in the heel, in the young athlete will be reviewed here. Heel and ankle pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link\">",
"     \"Clinical features and management of heel pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of foot pain, other than in the heel, in the young athlete include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pes planus (flat feet)",
"     </li>",
"     <li>",
"      Tendinitis of the tibialis posterior tendon",
"     </li>",
"     <li>",
"      Pes cavus (high-arched feet)",
"     </li>",
"     <li>",
"      Plantar fasciitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link\">",
"       \"Plantar fasciitis and other causes of heel pain\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tendinitis of the flexor digitorum longus tendon (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical features and management of ankle pain in the young athlete\", section on 'Flexor digitorum longus tendinitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the midfoot, metatarsals, and phalanges (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link\">",
"       \"Foot fractures (other than metatarsal or phalangeal) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=see_link\">",
"       \"Metatarsal and toe fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nerve pain caused by entrapment",
"     </li>",
"     <li>",
"      Lofgren syndrome (hilar adenopathy, acute polyarthritis, and erythema nodosum) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Lofgren's syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sarcoidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Musculoskeletal'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Morton neuroma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H38750749#H38750749\">",
"       \"Overview of running injuries of the lower extremity\", section on '(Mortons) neuroma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bunions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1960?source=see_link\">",
"       \"Hallux valgus deformity (bunion)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tarsal coalition (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the causes of limp in children\", section on 'Tarsal coalition'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pes planus, tibialis posterior tendinitis, and pes cavus are discussed here.",
"   </p>",
"   <p>",
"    Plantar fasciitis, flexor digitorum longus tendinitis, and nerve entrapment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and management of heel pain in the young athlete\", section on 'Plantar fasciitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link\">",
"     \"Plantar fasciitis and other causes of heel pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal system involvement may occur in as many as 10 percent of patients with sarcoidosis. Affected patients can present with an acute polyarthritis, usually occurring in association with erythema nodosum and occasionally with acute uveitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bunions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1960?source=see_link\">",
"     \"Hallux valgus deformity (bunion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RIGID PES PLANUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pes planus and flat feet are the terms used to describe feet with moderate or complete loss of the longitudinal arch. Pes planus can be classified radiographically according to the degree of depression of the lateral talometatarsal angle. However, a clinical classification can also be used for evaluation and treatment of this common condition. The clinical classification divides pes planus into two general categories: rigid and flexible. This distinction depends upon the mobility of the tarsal and subtalar joints [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rigid pes planus is diagnosed when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Range of motion at the tarsal and subtalar joints is decreased, and",
"     </li>",
"     <li>",
"      The arch does not increase with toe raising.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings also may occur in tarsal coalition and peroneal spasticity. CT scan may be used to determine whether tarsal coalition is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the causes of limp in children\", section on 'Tarsal coalition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FLEXIBLE PES PLANUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible pes planus may be physiologic or pathologic depending upon other associated conditions such as ligamentous laxity, motor weakness in the muscles of the foot, bony abnormalities, or a generalized syndrome. Flexible pes planus has three types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Type I",
"      </strong>",
"      &ndash; Functional flat foot (calcaneovalgus)",
"     </li>",
"     <li>",
"      <strong>",
"       Type II",
"      </strong>",
"      &ndash; Hypermobile flat foot with associated ligamentous laxity and \"tight heel cords.\"",
"     </li>",
"     <li>",
"      <strong>",
"       Type III",
"      </strong>",
"      &ndash; Clinical pes planus associated with tibialis posterior tendon dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional flat foot is the most common type of flat foot among athletes. It is physiologic and is simply a depression of the longitudinal arch that is associated with varying amounts of heel eversion (ie, calcaneovalgus heel).",
"   </p>",
"   <p>",
"    Functional flat foot is not usually a cause of disability and is not necessarily painful. Low arches in these individuals are considered to be a sign of a strong, stable foot rather than of weakness in the muscles that move the foot. Radiographs are not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best treatment is an adequately supported heel counter (the firm part of the shoe that surrounds the heel) and a well-constructed, cushioned shoe. Rigid orthotics usually are contraindicated because imposing an arch may cause pain and additional symptoms. Working with a physical therapist to decrease external rotation of the hip during walking and running may help to decrease the amount of functional pronation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have hypermobile flat foot with associated ligamentous laxity and \"tight heel cords,\" the ligamentous laxity may be familial or part of a generalized syndrome such as Ehlers-Danlos, Marfan, Down, or osteogenesis imperfecta. The condition can be aggravated by contracture of the triceps surae (gastrocnemius-soleus complex) and peroneal muscles (",
"    <a class=\"graphic graphic_picture graphicRef71142 \" href=\"UTD.htm?7/35/7728\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine radiography of type II flexible flat feet is not indicated. Obtain radiographs if the feet are painful and have restricted motion or if the deformity is so severe that orthosis or surgery is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/3\">",
"     3",
"    </a>",
"    ]. Painful causes of flexible flat feet include tarsal coalition, vertical talus, or an accessory navicular bone.",
"   </p>",
"   <p>",
"    Treatment is directed at the tight Achilles tendon. Passive stretching exercises are effective for mild cases. Moderate and severe contractures may require treatment with serial stretching and cast application. Semirigid or even rigid orthoses may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical pes planus associated with tibialis posterior tendon dysfunction can often be confused with type II flexible pes planus but it is a distinct clinical entity. Type III flexible pes planus is uncommon in patients who are younger than 20 years but is often overlooked in those who are older than 50 years. It may be seen in dancers, ice skaters, and athletes who participate in running sports that require rapid changes in direction (eg, basketball, tennis, soccer, ice hockey) because this change places increased stress across the tibialis posterior tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine radiography of type III flexible flat feet is not indicated. Obtain radiographs if the feet are painful and have restricted motion, or if the deformity is so severe that orthosis or surgery is being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TIBIALIS POSTERIOR TENDON DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibialis posterior muscle inverts and plantar flexes the foot and supports the medial longitudinal arch [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/4\">",
"     4",
"    </a>",
"    ]. Tibialis posterior tendon (TPT) dysfunction evolves through a series of stages, which are quite distinct and important to recognize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stage 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;During stage 1, TPT tendon length is normal. There is a peritendinitis or tendon degeneration. The patient has mild to moderate pain symptoms along the course of the TPT, most classically a few centimeters distal to the tip of the medial malleolus and along the course of the tendon to its major attachment at the undersurface of the navicular bone (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Swelling may be appreciated when viewing the standing patient from behind. At this stage, however, the forefoot is not abducted to cause \"too many toes\" to be seen when the patient is observed from behind. The single heel rise is a good test for TPT strength. The sequence in the normal individual is activation of the TPT, which inverts and locks the hindfoot, followed by contraction of the gastrocnemius-soleus complex, which completes the heel raise. In a patient with stage 1 TPT, the single heel rise may reveal mild weakness.",
"   </p>",
"   <p>",
"    The treatment of TPT should be directed by a physician who is comfortable with musculoskeletal issues (eg, orthopedic or sports medicine specialist, or experienced primary care practitioner). The treatment of stage I TPT dysfunction is conservative and includes modification of activity, NSAIDs, and orthotics. Conservative therapy should be tried for three months. Intractable cases will require surgery. It is imperative that aggressive treatment be initiated to prevent stage 2, in which the TPT tendon elongates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stage 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;During stage 2, the TPT tendon elongates and the hindfoot becomes mobile. Stage 2 typically develops after several months of symptoms. Pain is present along the whole length of the TPT; swelling and tenderness are present inferior and posterior to the medial malleolus. The forefoot is abducted, and \"too many toes\" are seen when the patient is observed from behind. The single heel raise reveals marked weakness.",
"   </p>",
"   <p>",
"    Plain radiographs may help to distinguish TPT from a stress fracture in the same anatomic region (eg, the navicular bone) and may rule out other bony problems such as an accessory navicular bone. However, as the pathology to the TPT progresses, more characteristic radiographic findings develop [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/4\">",
"     4",
"    </a>",
"    ]. In the antero-posterior radiographic view, the forefoot is abducted in relation to the hindfoot. The navicular bone subluxes from the head of the talus, and the angle between the long axis of the talus and the calcaneus increases. The lateral view radiograph reveals a sagging of the long axis of the talonavicular joint and divergence of the long axis of the talus from the calcaneus.",
"   </p>",
"   <p>",
"    MRI can be highly sensitive and specific for intratendinous pathology, but considerable variability in equipment, scan protocol, and physician interpretation may lead to suboptimal diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/4\">",
"     4",
"    </a>",
"    ]. CT is not usually helpful in demonstrating intratendinous TPT pathology. The treatment of stage 2 TPT dysfunction is surgical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stage 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stage 3 TPT dysfunction, the TPT has ruptured, the static supports of the foot have been damaged, and the hindfoot is rigid. A fixed, rigid flat foot develops. The deformity is the most dramatic finding. Surgical arthrodesis is the usual treatment, especially if the pain is severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PES CAVUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pes cavus, or high-arched foot, is a condition in which the longitudinal arch is abnormally elevated due to a fixed equinus deformity of the forefoot on the hindfoot [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/5\">",
"     5",
"    </a>",
"    ]. Equinus, which means \"horse-like,\" describes the deformity of plantarflexion at the ankle or within the foot. Equinus deformity often is part of a cavus foot. The cavus foot usually is stable, often has a limited range of motion, and frequently absorbs shock poorly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of pes cavus include neuromuscular disease, talipes equinovarus (residual clubfoot, either treated or untreated), and traumatic and idiopathic events. Pes cavus should be considered a manifestation of neuromuscular disease with dynamic muscle imbalance unless proven otherwise. This problem is usually best managed by an orthopedic specialist because of the progressive nature of the deformity. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two forms of the cavus foot deformity. One has an inverted calcaneus with a tight heel cord (the cavovarus foot). The second has a high arch with a normal heel alignment, usually from weak calf muscles and increased dorsiflexion of the heel with increased plantarflexion of the forefoot. This form is called calcaneocavus.",
"   </p>",
"   <p>",
"    The symptoms of the cavus foot can be static or progressive. The course is typically static in idiopathic cavus foot and progressive if the deformity is caused by a neurologic disease. Patients with idiopathic cavus foot prefer to wear shoes or boots with elevated heels to relieve the stress on the tight heel cords and the plantar fascia.",
"   </p>",
"   <p>",
"    On examination, the deformity is present with and without weightbearing. The toes may be clawed. Asymmetry of the muscle bulk of the calves should be evaluated with the patient standing. Gait should be evaluated for the presence of foot drop. The heel cords should be tested for tightness by determining the extent of dorsiflexion of the foot. Patients with tight heel cords are unable to dorsiflex the foot beyond the neutral position. The lower spine should be evaluated for neurocutaneous markings (suggestive of spinal dysraphism). Muscle strength and sensation of the foot should be tested.",
"   </p>",
"   <p>",
"    For the purpose of evaluation and treatment of the young athlete with a cavus foot, categorizing the deformity according to function (eg, flexible, semiflexible, and rigid) is helpful.",
"   </p>",
"   <p>",
"    These categories can be defined by determining the mobility of the hindfoot on the forefoot using the Coleman standing lateral block test and the Carroll test (",
"    <a class=\"graphic graphic_picture graphicRef68127 \" href=\"UTD.htm?2/62/3044\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Coleman standing lateral block test, the patient stands on a 1- to 1.5-inch thick wooden block, bearing weight on the heel with the lateral border of the foot on the block [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/2\">",
"       2",
"      </a>",
"      ]. The first through third metatarsals hang freely off the medial border of the block into plantarflexion and pronation. The examiner observes the position of the hindfoot. If the foot drops (calcaneovalgus), the subtalar joint is flexible; if the foot goes to neutral, the subtalar joint is semiflexible and forefoot problems may be present (eg, rigid plantarflexed first ray); if the foot remains in varus, the subtalar joint is rigid.",
"     </li>",
"     <li>",
"      The Carroll test uses a similar technique [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23190/abstract/2\">",
"       2",
"      </a>",
"      ]. The patient stands on a block, bearing his or her weight on the heel; the forefoot is off the block. If the patient has good midfoot mobility, the rearfoot varus will fall into neutral position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiologic evaluation of patients with pes cavus should include weightbearing radiographs of the foot and ankle. Radiographs of the spine should also be obtained to rule out spinal dysraphism. An MRI of the spine may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography, muscle biopsy, and nerve conduction studies may be necessary to determine the specific neurologic problem (eg, myopathy versus neuropathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pes cavus depends upon the etiology. Neuromuscular pes cavus is usually best managed by orthopedic and neurologic specialists because of the progressive nature of the deformity. Management may include bracing, ankle foot orthotics, or surgery in addition to treatment of the underlying neurologic problem. Idiopathic pes cavus may be managed by the primary care provider. Treatment includes orthotics to support the arch, provide shock absorption, and keep the foot and first ray (the first metatarsal and the two phalanges of the great toe) in neutral. Stretching of the plantar fascia and the heel cords is also beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751464\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foot pain in the young athlete can originate in the bones (fractures), ligaments (sprains), muscles and tendons, or fascia. Careful localization of the pain can help to narrow the differential diagnosis (",
"      <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of foot pain, other than in the heel, in the young athlete include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pes planus (flat feet)",
"     </li>",
"     <li>",
"      Tendinitis of the tibialis posterior tendon",
"     </li>",
"     <li>",
"      Pes cavus (high-arched feet)",
"     </li>",
"     <li>",
"      Plantar fasciitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link&amp;anchor=H2#H2\">",
"       \"Plantar fasciitis and other causes of heel pain\", section on 'Plantar fasciitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tendinitis of the flexor digitorum longus tendon (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical features and management of ankle pain in the young athlete\", section on 'Flexor digitorum longus tendinitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the midfoot, metatarsals, and phalanges (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=see_link\">",
"       \"Metatarsal shaft fractures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link\">",
"       \"Foot fractures (other than metatarsal or phalangeal) in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Morton neuroma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H38750749#H38750749\">",
"       \"Overview of running injuries of the lower extremity\", section on '(Mortons) neuroma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nerve pain caused by entrapment",
"     </li>",
"     <li>",
"      Lofgren syndrome (hilar adenopathy, acute polyarthritis, and erythema nodosum) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Lofgren's syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sarcoidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bunions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1960?source=see_link\">",
"       \"Hallux valgus deformity (bunion)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tarsal coalition (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the causes of limp in children\", section on 'Tarsal coalition'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751968\">",
"    <span class=\"h2\">",
"     Pes planus (flat feet)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical classification divides pes planus (flat feet) into two general categories: rigid and flexible. This distinction depends upon the mobility of the tarsal and subtalar joints. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rigid pes planus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Flexible pes planus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pes planus (flat feet), treatment depends on the underlying cause and degree of symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Flexible pes planus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751986\">",
"    <span class=\"h2\">",
"     Tibialis posterior tendon dysfunction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tibialis posterior tendon dysfunction causes pain a few centimeters distal to the tip of the medial malleolus and along the course of the tendon to its major attachment at the undersurface of the navicular bone. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tibialis posterior tendon dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of tibialis posterior tendon dysfunction initially consists of nonsteroidal antiinflammatory medications, modification of activities, rehabilitation, and orthotics in patients with Stage I (no tendon elongation). Surgical correction is necessary for patients who do not respond to nonoperative measures and those who develop tendon elongation or rupture. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tibialis posterior tendon dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15752013\">",
"    <span class=\"h2\">",
"     Pes cavus (high arched feet)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pes cavus, or high-arched foot, is a condition in which the longitudinal arch is abnormally elevated due to a fixed equinus deformity of the forefoot on the hindfoot. Equinus, which means \"horse-like,\" describes the deformity of plantarflexion at the ankle or within the foot. Equinus deformity often is part of a cavus foot. The cavus foot usually is stable, often has a limited range of motion, and frequently absorbs shock poorly. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pes cavus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pes cavus should be considered a manifestation of neuromuscular disease with dynamic muscle imbalance unless proven otherwise. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pes cavus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of pes cavus depends upon the etiology. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23190/abstract/1\">",
"      Yagerman SE, Yeagerman SE, Cross MB, et al. Evaluation and treatment of symptomatic pes planus. Curr Opin Pediatr 2011; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     Techdijan MO. Clinical Pediatric Orthopedics: The Art of Diagnosis and the Principles of Management, Appleton and Lange, Philadelphia 1997.",
"    </li>",
"    <li>",
"     Kasser JR. The foot. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2001. p.1257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23190/abstract/4\">",
"      Conti SF. Posterior tibial tendon problems in athletes. Orthop Clin North Am 1994; 25:109.",
"     </a>",
"    </li>",
"    <li>",
"     Reid DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, London 1992.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6521 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23190=[""].join("\n");
var outline_f22_41_23190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15751464\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RIGID PES PLANUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FLEXIBLE PES PLANUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TIBIALIS POSTERIOR TENDON DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stage 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stage 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PES CAVUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15751464\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15751968\">",
"      Pes planus (flat feet)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15751986\">",
"      Tibialis posterior tendon dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15752013\">",
"      Pes cavus (high arched feet)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/44/711\" title=\"figure 1\">",
"      Location foot ankle pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6521|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/35/7728\" title=\"picture 1\">",
"      Surface contour leg muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/62/3044\" title=\"picture 2\">",
"      Hindfoot forefoot mobility test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=related_link\">",
"      Clinical features and management of heel pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=related_link\">",
"      Evaluation of foot and ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=related_link\">",
"      Foot fractures (other than metatarsal or phalangeal) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1960?source=related_link\">",
"      Hallux valgus deformity (bunion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=related_link\">",
"      Metatarsal and toe fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=related_link\">",
"      Metatarsal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=related_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_41_23191="Thyroid nodules and cancer in children";
var content_f22_41_23191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid nodules and cancer in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23191/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/41/23191/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 2 percent of children develop solitary thyroid nodules. Most of these are benign, including inflammatory lesions or follicular adenomas, but a few are malignant.",
"   </p>",
"   <p>",
"    The thyroid gland in children is particularly susceptible to irradiation and carcinogenesis. As a result, children with thyroid cancer tend to present with advanced disease. As compared with adults, children with thyroid cancer display a greater frequency of lymph node metastases and distant metastases at the time of diagnosis and higher rates of recurrence during the first decade after diagnosis. Despite these characteristics, children with thyroid cancer generally have a good prognosis.",
"   </p>",
"   <p>",
"    The evaluation of a child presenting with a thyroid nodule, and an overview of the treatment of thyroid carcinoma is discussed in this topic review. Congenital and acquired goiter and thyroid cysts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=see_link\">",
"     \"Congenital and acquired goiter in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study conducted in the southwestern United States, thyroid nodules detectable by palpation were present in 1.8 percent of school children between the ages of 11 and 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/1\">",
"     1",
"    </a>",
"    ]. In a follow-up study 20 years later, nodules were present in only 0.45 percent of the same subjects, showing that nodules disappeared in 75 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/2\">",
"     2",
"    </a>",
"    ]. Most thyroid nodules in children are benign. Estimates of the rate of malignancy vary widely but are probably less than one percent.",
"   </p>",
"   <p>",
"    The following calculations suggest that the proportion of thyroid nodules that are malignant in children is less than 1 percent: In a report from the Surveillance, Epidemiology and End Results (SEER) registry from 1973 through 2004, there were a total of 1753 pediatric patients with thyroid cancer, with an annual incidence of 0.54 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/3\">",
"     3",
"    </a>",
"    ]. An annual incidence of 0.54 per 100,000 is equivalent to a prevalence of 10 per 100,000 children aged 1 to 18 years. If 1.8 per 100 children have solitary nodules, but only 10 per 100,000 children develop cancer, approximately only 1 in 180 solitary nodules represents thyroid cancer (0.5 percent). Older studies had suggested substantially higher malignancy rates in children with thyroid nodules, ranging from 2 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The higher percentages likely represent \"referral bias\" of children with increased risk factors for thyroid cancer.",
"   </p>",
"   <p>",
"    The SEER registry reported an increasing incidence of thyroid cancer in children, rising 1.1 percent per year over the 31 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that the thyroid gland in children compared with that in adults is more susceptible to the carcinogenic effects of irradiation. Children exposed to external irradiation for a variety of conditions and children with Hodgkin lymphoma or other tumors of the head and neck treated with irradiation all have a higher incidence of thyroid nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cancer during adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The pathogenesis of radiation-induced thyroid cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic syndromes are associated with thyroid cancer: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gardner syndrome, characterized by familial adenomatous polyps in the gastrointestinal tract and papillary thyroid cancer, is an autosomal dominant disorder caused by a mutation in the APC (adenomatous polyposis coli) gene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"       \"Gardner syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome are autosomal dominantly inherited PTEN hamartoma tumor syndromes that are characterized by hamartomas in the skin and other tissues and an increased predisposition to thyroid cancer. Both are associated with germline mutations in the PTEN (phosphatase and tensin homolog) gene (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462459902#H462459902\">",
"       \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Cowden syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460023#H462460023\">",
"       \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Bannayan-Riley-Ruvalcaba syndrome'",
"      </a>",
"      ). Clinical features associated with PTEN mutations in pediatric patients are [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/8\">",
"       8",
"      </a>",
"      ]: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Macrocephaly (100 percent)",
"     </li>",
"     <li>",
"      Autism or developmental delay (82 percent)",
"     </li>",
"     <li>",
"      Penile freckling or other benign skin lesions (60 percent)",
"     </li>",
"     <li>",
"      Vascular features (eg, arteriovenous malformations or hemangiomas) (29 percent)",
"     </li>",
"     <li>",
"      Gastrointestinal polyps (14 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carney complex type 1 is characterized by a primary pigmented nodular adrenocortical disease (PPNAD), other endocrine tumors including papillary or follicular thyroid cancer, and nonendocrine tumors such as myxomas and breast adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/9\">",
"       9",
"      </a>",
"      ]. It is associated with a mutation in the protein kinase A regulatory subunit type 1-alpha gene (PPRKAR1&alpha;). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link&amp;anchor=H5#H5\">",
"       \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\", section on 'Carney complex (CNC)'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Werner syndrome is characterized by connective tissue disease causing symptoms of premature aging (progeria) and increased risk for osteosarcoma, soft tissue sarcomas, and follicular or papillary thyroid cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 2 (MEN2) is associated with medullary thyroid cancer, and is transmitted in an autosomal dominant fashion. Three distinct subtypes of MEN2 are associated with medullary thyroid carcinoma (MTC): MEN2A; MEN2B; and familial medullary thyroid cancer (FMTC). These disorders are caused by mutations in the RET proto-oncogene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"       \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"       \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Familial patterns of inheritance for non-medullary thyroid cancer are also seen without the above syndromes, and linkage analysis has identified several genetic loci that may contribute to this predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid cancer has been found in children with thyroglossal duct cysts, and it also has been reported in children with congenital goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/10\">",
"     10",
"    </a>",
"    ]. In these situations, it appears that chronic TSH stimulation may play a pathogenic role. In addition, there is some evidence that the risk of thyroid cancer is increased in autoimmune thyroid disease, including Hashimoto thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/11\">",
"     11",
"    </a>",
"    ] and Graves&rsquo; disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=see_link&amp;anchor=H23#H23\">",
"     \"Congenital and acquired goiter in children\", section on 'Thyroglossal duct cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, the causes of solitary thyroid nodules in children are inflammatory lesions, benign thyroid adenomas (usually follicular adenomas), thyroid cysts, and thyroid carcinomas. Follicular adenomas are the most common tumor (",
"    <a class=\"graphic graphic_table graphicRef57701 \" href=\"UTD.htm?8/25/8604\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among the 1753 childhood thyroid cancers reported by the SEER registry, 83 percent had papillary thyroid cancer (60 percent papillary and 23 percent follicular variant of papillary cancer), 10 percent had follicular thyroid cancer, 5 percent had medullary thyroid carcinoma, and 2 percent had \"other\" type of thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both differentiated thyroid cancer and medullary thyroid carcinoma (MTC) in children usually present as asymptomatic solitary nodules. The vast majority of children with nodules have normal thyroid function. Toxic adenomas are relatively rare in children; when present, these are associated with clinical and laboratory features of hyperthyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiated thyroid cancer &mdash; Differentiated thyroid cancer includes papillary and follicular thyroid carcinomas. Clinical findings that increase the likelihood of cancer are male sex, a history of external radiation to the head and neck or exposure to nuclear fallout, a history of rapid growth of the nodule, a firm or fixed mass, hoarseness or dysphagia, and cervical adenopathy.",
"      <br/>",
"      <br/>",
"      Prepubertal children with thyroid cancer tend to have more advanced disease at presentation as compared with adolescents and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This was illustrated in a review of 540 children from nine large centers that found 71 to 90 percent of the children had spread to regional lymph nodes, 20 to 60 percent had extracapsular extension with invasion of the trachea, and 30 percent had involvement of the recurrent laryngeal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/14\">",
"       14",
"      </a>",
"      ]. Distant metastases most commonly go to the lungs (10 to 28 percent), followed by the bones and brain.",
"     </li>",
"     <li>",
"      Medullary thyroid carcinoma (MTC) &mdash; Children with MTC typically present with a solitary nodule, or they are discovered incidentally when a family member is diagnosed with MTC, typically as part of multiple endocrine neoplasia type 2A (MEN2A) or MEN2B. Children with MEN2B may have a Marfanoid body habitus, mucosal neuromas of the tongue and conjunctivae, and medullated (thickened) corneal nerves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thyroid function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children presenting with thyroid nodule(s), it is helpful to initially assess thyroid function. If the serum TSH is suppressed, this likely represents a hyperfunctioning (\"hot\") nodule. This is the one finding where a thyroid uptake and scan are indicated (generally using I-123), confirming increased uptake within the nodule and absent or reduced uptake in the remainder of the gland. The majority of cases, however, will be euthyroid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neck ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step generally is an ultrasound examination of the neck. This will help to determine whether there are one or multiple nodules and their size. Certain characteristics of a nodule on sonography, such as hypoechogenicity, irregular margins with lack of a capsule, microcalcifications, and increased vascularity, are associated with an increased risk of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/15\">",
"     15",
"    </a>",
"    ]. On the other hand, simple cysts rarely are cancerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fine-needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine-needle aspiration (FNA) is the single most useful test in separating benign lesions from cancer. FNA, long used to evaluate nodules in adults, shows the same diagnostic accuracy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. An experienced team, usually including a radiologist and cytopathologist, is required to perform and interpret the FNA. Ultrasound guidance is sometimes required for smaller nodules or those farther from the surface of the gland. A case can be made that all children should undergo FNA under ultrasound guidance, as this improves diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with non-medullary thyroid cancer should be carefully evaluated for clinical features of a PTEN hamartoma syndrome (Cowden or Bannayan-Riley-Ruvalcaba syndrome), which include macrocephaly, developmental delay, penile freckling, and other benign skin lesions. Children with any of these associated features, particularly macrocephaly, should be tested for a PTEN mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462459990#H462459990\">",
"       \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Criteria for PTEN genetic testing'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Children at risk for MTC, usually based on discovery of a family member with MTC, should undergo RET proto-oncogene analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link&amp;anchor=H4#H4\">",
"       \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\", section on 'Inherited MTC'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Benign thyroid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine-needle aspirates read as \"benign\" can be monitored by periodic neck palpation and ultrasound examinations. A significant increase in size may lead to consideration of a repeat fine needle aspiration (FNA) or surgical excision (usually a lobectomy) because a small percentage of these \"benign nodules\" harbors cancer. Specimens read as \"nondiagnostic or unsatisfactory\" or \"follicular lesion of undetermined significance\" should undergo repeat FNA under ultrasound guidance. Specimens read as \"follicular neoplasm\" carry a significant risk (10 to 25 percent in adults) of follicular cancer or follicular variant papillary cancer and should undergo surgical excision.",
"   </p>",
"   <p>",
"    If diagnostic studies are consistent with a \"toxic adenoma\" (suppressed TSH level, I-123 uptake in the nodule with the rest of the gland not visible), we generally recommend surgical excision, because these are unlikely to resolve spontaneously. Radioactive iodine ablation of the toxic adenoma is an option in older adolescents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differentiated thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the perception that many thyroid nodules in children are carcinomas, most nodules are surgically excised. However, as experience with FNA biopsy grows, children are increasingly being managed in a manner similar to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Papillary thyroid cancer in children tends to be multifocal. Thus, total or near-total thyroidectomy is the most common treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/22\">",
"     22",
"    </a>",
"    ]. One recent analysis of 1199 patients found that surgical complications were higher in children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/23\">",
"     23",
"    </a>",
"    ]. This study reported that recurrent laryngeal nerve injury occurred in 3.8 percent of children aged 0 to 6 years, 1.1 percent in children aged 7 to 12 years, and 0.6 percent in children aged 13 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/23\">",
"     23",
"    </a>",
"    ]. Radical neck dissection is not indicated. It is important that surgery in children be performed by an experienced &ldquo;high-volume&rdquo; thyroid surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After thyroidectomy, most children are given radioactive iodine to ablate residual thyroid tissue or persistent disease, since radioiodine has been associated with a lower rate of locoregional recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, in the absence of a proven benefit on either disease-free survival or recurrence, we do not routinely recommend RAI ablation for patients with unifocal cancer &lt;1 cm without other high-risk features (distant metastases, vascular invasion, gross extrathyroidal extension, worrisome histologic subtypes such as tall cell, columnar cell, insular, or poorly differentiated histologies), or for patients with multifocal cancer when all foci are &lt;1 cm and there are no other high-risk features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Radioiodine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If radioactive iodine is indicated, either for follow-up diagnostic studies or for thyroid remnant ablation, recombinant human thyrotropin (TSH) preparation in children has been shown to be as effective as thyroid hormone withdrawal in achieving the desired elevation in TSH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children should be treated with T4 to keep the serum TSH concentration at the lower limit of normal. Serum thyroglobulin determinations are useful in monitoring for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37496?source=see_link\">",
"     \"Serum thyroglobulin in the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medullary thyroid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total thyroidectomy is the treatment of choice for children with MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Thyroidectomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For pediatric patients with a high risk for developing MTC because of RET gene mutations, &ldquo;prophylactic&rdquo; total thyroidectomy is recommended during infancy or early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/20\">",
"     20",
"    </a>",
"    ]. The recommended age of \"prophylactic\" thyroidectomy in an asymptomatic but RET gene-positive infant or child is based on their risk level, which correlates with the RET mutation. In patients at higher risk mutations (MEN2B), thyroidectomy is recommended during the first year of life. In patients with lower risk mutations, who typically have familial MTC or MEN2A, thyroidectomy is usually performed during early childhood (",
"    <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Prophylactic thyroidectomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite having more widespread disease at discovery, children with thyroid cancer have a survival rate that appears to be better than in adults, even with recurrence of disease. This is illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multicenter review cited above, recurrence rates ranged from 10 to 35 percent with involvement of the thyroid bed, regional nodes, or distant sites [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/14\">",
"       14",
"      </a>",
"      ]. However, only 2.5 percent died of their disease over periods ranging from 12 to 33 years. The presence of regional lymph node spread does not affect survival.",
"     </li>",
"     <li>",
"      A retrospective review of 36 children with papillary thyroid cancer from a single center reported a recurrence rate of 47 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients were initially treated with either subtotal (18 patients) or total thyroidectomy (18 patients), and 23 also received postoperative radioactive iodine. Recurrence was more common in patients with lymph node involvement and those with multiple nodules. Recurrence occurred in 5 patients with subtotal and in 12 patients with total thyroidectomy, developing at a median of 7 months (range 1 to 43 months) after the first operation. Two recurrences were within the thyroid bed, and the others were localized to lymph nodes. Operative resection followed by selective radioactive iodine ablation successfully treated 14 of the 17 patients with recurrent disease. There were no deaths in any of the patients with recurrent disease over a mean follow-up period of 65 months (range 15 to 144 months).",
"     </li>",
"     <li>",
"      In the SEER registry report of 1753 children with thyroid cancer followed over 31 years, the 5-, 15- and 30-year survival rates for patients with papillary thyroid cancer were 98, 87, and 91 percent, respectively. Survival rates were similar for patients with follicular thyroid cancer (96, 95, and 92 percent, respectively) but were lower for patients with medullary thyroid cancer (95, 86, and 15 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23191/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 0.45 to 1.8 percent of children and adolescents have thyroid nodules. About 1 percent of these are malignant thyroid cancers (eg, differentiated thyroid carcinoma or medullary thyroid carcinoma). Most thyroid nodules are asymptomatic because the majority of children are euthyroid. Children with a toxic adenoma will have clinical and laboratory features of hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Thyroid cancer in children is associated with radiation exposure (eg, treatment for head and neck cancers), Gardner syndrome and Cowden syndrome, and multiple endocrine neoplasia type 2. Rarely, it has been found in association with thyroglossal duct cysts and congenital goiters associated with dyshormonogenesis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most thyroid cancers in children are differentiated (papillary or follicular). About 5 percent are medullary thyroid carcinomas, which usually occur in association with multiple endocrine neoplasia type 2. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with thyroid nodules should be evaluated with thyroid function tests, thyroid ultrasound, and fine needle aspiration of the lesion. Those at risk for medullary thyroid cancer, usually based on discovery of a family member with MTC, should undergo RET proto-oncogene analysis. Children with non-medullary thyroid cancer should be carefully evaluated for clinical features of a PTEN hamartoma syndrome (Cowden or Bannayan-Riley-Ruvalcaba syndrome), which include macrocephaly and autism or developmental delay. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Papillary thyroid cancer in children is usually multifocal, and so the surgery of choice is total or nearly total thyroidectomy, followed by radioactive iodine to ablate residual thyroid tissue or persistent disease. Children with micro-carcinomas (&lt;1.0 cm) are cured by total thyroidectomy, and may not need radioactive iodine treatment. Children should be treated with T4 to keep the serum TSH concentration at the lower limit of normal. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differentiated thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with medullary thyroid cancer are treated with total thyroidectomy. Infants or children who are at risk for MTC because of a confirmed RET gene mutation are treated with prophylactic thyroidectomy; the age at which thyroidectomy is suggested depends on the risk level, as determined by detailed analysis of the RET mutation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Medullary thyroid carcinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Prophylactic thyroidectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term survival rates for papillary or follicular thyroid cancer are over 90 percent. Five-year survival rates for medullary thyroid cancer are also over 90 percent, but 30-year survival rates are poor. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/1\">",
"      Rallison ML, Dobyns BM, Keating FR Jr, et al. Thyroid nodularity in children. JAMA 1975; 233:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/2\">",
"      Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 1991; 91:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/3\">",
"      Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009; 156:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/4\">",
"      Kirkland RT, Kirkland JL, Rosenberg HS, et al. Solitary thyroid nodules in 30 children and report of a child with a thyroid abscess. Pediatrics 1973; 51:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/5\">",
"      Hung W. Solitary thyroid nodules in 93 children and adolescents. a 35-years experience. Horm Res 1999; 52:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/6\">",
"      Davies SM. Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. Pediatr Blood Cancer 2007; 48:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/7\">",
"      Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer 2009; 125:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/8\">",
"      Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/9\">",
"      Bonora E, Tallini G, Romeo G. Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. J Oncol 2010; 2010:385206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/10\">",
"      Alzahrani AS, Baitei EY, Zou M, Shi Y. Clinical case seminar: metastatic follicular thyroid carcinoma arising from congenital goiter as a result of a novel splice donor site mutation in the thyroglobulin gene. J Clin Endocrinol Metab 2006; 91:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/11\">",
"      Corrias A, Cassio A, Weber G, et al. Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. Arch Pediatr Adolesc Med 2008; 162:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/12\">",
"      Berker D, Isik S, Ozuguz U, et al. Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine 2011; 39:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/13\">",
"      Lazar L, Lebenthal Y, Steinmetz A, et al. Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr 2009; 154:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/14\">",
"      Feinmesser R, Lubin E, Segal K, Noyek A. Carcinoma of the thyroid in children--a review. J Pediatr Endocrinol Metab 1997; 10:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/15\">",
"      Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/16\">",
"      Corrias A, Einaudi S, Chiorboli E, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab 2001; 86:4644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/17\">",
"      Arda IS, Yildirim S, Demirhan B, Firat S. Fine needle aspiration biopsy of thyroid nodules. Arch Dis Child 2001; 85:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/18\">",
"      Izquierdo R, Shankar R, Kort K, Khurana K. Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. Thyroid 2009; 19:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/19\">",
"      Rio AL, Biscolla RP, Andreoni DM, et al. [Evaluation of clinical, laboratorial and ultrasonographic predicting factors of malignancy in thyroid nodules]. Arq Bras Endocrinol Metabol 2011; 55:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/20\">",
"      American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/21\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/22\">",
"      Rachmiel M, Charron M, Gupta A, et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 2006; 19:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/23\">",
"      Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008; 93:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/24\">",
"      Rivkees SA, Mazzaferri EL, Verburg FA, et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 2011; 32:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/25\">",
"      Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002; 12:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/26\">",
"      Handkiewicz-Junak D, Wloch J, Roskosz J, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007; 48:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/27\">",
"      Luster M, Handkiewicz-Junak D, Grossi A, et al. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab 2009; 94:3948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/28\">",
"      Kirk JM, Mort C, Grant DB, et al. The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children. Med Pediatr Oncol 1992; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23191/abstract/29\">",
"      Palmer BA, Zarroug AE, Poley RN, et al. Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence. J Pediatr Surg 2005; 40:1284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5835 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23191=[""].join("\n");
var outline_f22_41_23191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thyroid function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neck ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fine-needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Benign thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medullary thyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5835\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5835|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/25/8604\" title=\"table 1\">",
"      Major causes of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/12/32972\" title=\"table 2\">",
"      MEN2 timing thyroidectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=related_link\">",
"      Congenital and acquired goiter in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37496?source=related_link\">",
"      Serum thyroglobulin in the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_41_23192="Arrhythmia in athletes";
var content_f22_41_23192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arrhythmia in athletes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Antonio Pelliccia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23192/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/41/23192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are not infrequently documented in athletes and can be a source of morbidity and mortality, particularly ventricular tachyarrhythmias leading to sudden cardiac death (SCD). It is therefore important to establish guidelines for screening of athletes with two goals in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To document the presence of arrhythmia and underlying structural heart disease that place the athlete at risk for sudden death.",
"     </li>",
"     <li>",
"      To evaluate the importance of an arrhythmia in assessing the athlete's eligibility for competition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss specific arrhythmias or arrhythmia-related syndromes and their importance in athletes. The risk is related to the intensity and type of exercise (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of sudden death in athletes, particularly those with underlying heart disease, the approach to screening to prevent sudden death in athletes, and the management of conduction disturbances in athletes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=see_link\">",
"     \"Electrocardiographic abnormalities and conduction disturbances in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=see_link\">",
"     \"Screening to prevent sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope in an athlete is an important symptom that requires a thorough evaluation. A common cause of syncope in young athletes is neurally mediated (vasovagal) syncope, which is generally unassociated with cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This type of syncope is due to neurally mediated mechanisms, but hypovolemia from unreplaced fluid losses may contribute in athletes. Athletes (especially those engaged in endurance disciplines) may also be more susceptible to neurally mediated syncope by nature of their increased vagal tone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, underlying structural heart disease and other causes should be eliminated before considering neurally mediated syncope as the etiology. Among the pathologic cardiac causes of exertional syncope are ventricular tachycardia and obstruction resulting from hypertrophic cardiomyopathy or aortic stenosis, and hypotension due to vagally-mediated vasodepression in patients with hypertrophic cardiomyopathy. Exercise associated syncope may also be related to hyponatremia or hyperthermia as a result of intense or prolonged exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H274573#H274573\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between syncope and athletes was best evaluated in a report of 7568 young athletes (mean age 16 years), 474 of whom (6.2 percent) reported a syncopal spell in the preceding five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/4\">",
"     4",
"    </a>",
"    ]. Syncope was unrelated to exercise in 411 (87 percent), postexertional in 57 (12 percent), and exertional in six (1 percent). All episodes of nonexertional or postexertional syncope were diagnosed as vasovagal (neurally mediated syncope), situational, or postexertional postural hypotension based upon the clinical history. In the six patients with exertional syncope, further testing identified one case of hypertrophic cardiomyopathy, one case of right ventricular outflow tract tachycardia, and four cases of neurocardiogenic syncope. At six years of follow-up, the rate of syncope recurrence was 2 per 100 patient-years. There were no other adverse cardiovascular events in follow-up.",
"   </p>",
"   <p>",
"    Exercise testing is useful and should be performed in a manner to replicate the clinical scenario. For example, if syncope or presyncope occurs well into a distance run, then a prolonged stress test performed at the level of exertion during the sport should be performed. In addition, ambulatory monitors worn during the sport are advised as the most reliable way to record the syncope. Echocardiography should be obtained in all patients. Invasive electrophysiologic testing may be necessary when an arrhythmia is an important consideration, in athletes who have underlying cardiac disease, or when no cause for the syncope has been established after other testing has been performed.",
"   </p>",
"   <p>",
"    Many patients with exercise-induced syncope develop syncope in association with hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia during upright tilt table testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, there is concern about a lack of specificity of this test, especially in well-trained athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=see_link\">",
"     \"Upright tilt table testing in the evaluation of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with syncope should have a complete cardiac evaluation to exclude structural heart disease. Those who have a fully negative evaluation with reasonable exclusion of underlying cardiac disease can safely participate in all sports.",
"     </li>",
"     <li>",
"      Athletes with syncope or presyncope should not participate in sports where the likelihood of even a momentary loss of consciousness may be hazardous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      potentially responsible for adverse events (such as scuba diving, climbing rocks, car racing, etc). Participation in all sports is permitted after the cause has been determined and, if necessary, treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SINUS AND AV NODE DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most well-trained endurance athletes have resting sinus bradycardia (heart rate &lt;60 beats per minute) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This has traditionally been attributed to increased vagal tone induced by exercise conditioning. However, there is some evidence that this may be due in part to alteration of the intrinsic properties of the sinoatrial and atrioventricular (AV) nodes. This was illustrated in report of electrophysiology study results in six trained athletes compared to six healthy male controls. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trained athletes had a longer baseline values for sinus cycle length, sinus node recovery time, and AV nodal Wenckebach.",
"     </li>",
"     <li>",
"      This difference sinus and AV nodal function persisted after both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      and double-adrenergic blockade with atropine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the persistence of these differences after autonomic blockade suggests that these phenomena are at least in part due to changes in the intrinsic physiology of the sinus and AV nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinus bradycardia and sinus tachycardia that are appropriate for the clinical situation are not considered abnormal and further testing or therapy is not necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=see_link\">",
"     \"Sinus bradycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link\">",
"     \"Sinus tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sinus arrhythmia and a wandering pacemaker are frequent in well trained individuals, again due to increased vagal tone. No testing is necessary unless the arrhythmia results in inappropriately slow heart rates associated with symptoms.",
"   </p>",
"   <p>",
"    Asymptomatic sinus pauses or sinus arrest of less than three-second's duration are probably normal in athletes and of no clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/11\">",
"     11",
"    </a>",
"    ]. They often occur in association with sinus bradycardia. However, longer pauses, sinoatrial exit block, and sick sinus syndrome are abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .) Further evaluation with a 12 lead ECG, 24-hour ambulatory monitoring, an echocardiogram, and exercise testing is justified in such individuals. Electrophysiologic testing may be necessary in the athlete who is experiencing syncope or presyncope associated with these abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with a normal or structurally abnormal heart in whom a resting bradycardic rate increases appropriately during physical activity can participate in all competitive sports consistent with the limitations imposed by the structural heart disease. Periodic reassessment is important to determine that training does not aggravate the bradycardia.",
"     </li>",
"     <li>",
"      Athletes with symptoms including impaired consciousness or fatigue resulting from bradycardia should be restricted from competitive sports until appropriately treated. If the subject remains asymptomatic for two to three months during treatment, participation in all competitive sports is permitted after clinician re-evaluation (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with a symptomatic",
"      <span class=\"nowrap\">",
"       tachycardia/bradycardia",
"      </span>",
"      (sick sinus) syndrome or inappropriate sinus tachycardia should be restricted from participating in competitive sports. These patients should be treated and if they have no structural heart disease and are asymptomatic for two to three months, they can participate in all competitive sports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ATRIAL OR JUNCTIONAL PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial premature beats are common in the general population and in athletes, and are not generally associated with underlying structural heart disease or symptoms. Except for a 12 lead ECG, no further evaluation is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/441?source=see_link\">",
"     \"Supraventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Junctional premature beats are less common and, if there is no history to suggest a sustained arrhythmia, evaluation only requires a 12 lead ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 36th Bethesda Conference recommended that athletes with a structurally normal heart who have atrial or junctional premature beats, regardless of frequency, can participate in all competitive sports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]. However, consideration should be given to evaluation with exercise stress testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an ambulatory event monitor to be certain that the ectopic beats are not associated with sustained tachyarrhythmia. Athletes with underlying structural heart disease who have atrial or junctional premature beats can participate in competitive sports consistent with the limitations of the structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained atrial flutter, in the absence of a Wolff-Parkinson-White syndrome or an acute illness, is uncommon in athletes. A full cardiac evaluation, including echocardiogram, should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since there is a potential for 1:1 atrioventricular (AV) nodal conduction and very rapid ventricular rates, particularly when there is sympathetic stimulation, an exercise ECG stress test during treatment is essential if curative ablation is not anticipated. Typical atrial flutter is relatively easily cured with ablation procedures and generally should be performed in athletes with atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the evaluation and management of atrial flutter\", section on 'Maintenance of NSR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with atrial flutter in the absence of structural heart disease should be offered therapeutic resolution by radiofrequency ablation. Only when ablation is not possible, drug therapy is advised. Individuals who maintain a ventricular rate that increases and slows appropriately comparable to that of a normal sinus response in relation to the level of activity, while receiving therapy with AV nodal blocking drugs, can participate in class IA competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) with the warning that rapid 1:1 conduction still may occur. However, full participation in all competitive sports should not be allowed unless the athlete has been without atrial flutter for two to three months with or without drug treatment. The use of beta-blockers is prohibited in some competitive sports.",
"     </li>",
"     <li>",
"      Athletes with structural heart disease who have atrial flutter can participate in class IA competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) only after two to four weeks have elapsed without an episode of atrial flutter.",
"     </li>",
"     <li>",
"      Athletes without structural heart disease who have elimination of the atrial flutter by an ablation technique or surgery can participate in all competitive sports after two to four weeks without a recurrence, or in several days after an electrophysiologic study showing noninducibility of the atrial flutter in the presence of bidirectional isthmus block.",
"     </li>",
"     <li>",
"      Athletes in whom anticoagulation is deemed necessary cannot participate in competitive sports where the danger of bodily collision is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is a common arrhythmia that may be present intermittently or persistently. In young athletes, AF may occur in the absence of any structural heart disease or other provoking condition and is termed \"lone AF\". However, in older athletes, hypertension and coronary artery disease are common underlying conditions.",
"   </p>",
"   <p>",
"    Regardless of the age of the athlete, a cause for the arrhythmia should be sought. An echocardiogram is helpful in establishing the presence of structural heart disease. Additional evaluation includes a 12 lead ECG and determination of the ventricular rate response during physical activity; this can be established with 24-hour ambulatory monitoring or an exercise test that is comparable to the intended sport. For some patients with intermittent AF, the arrhythmia can be diagnosed with the use of an ambulatory monitor. Induction of the arrhythmia with electrophysiologic studies may be necessary in occasional patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of atrial fibrillation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with asymptomatic atrial fibrillation in the absence of structural heart disease who maintain a ventricular rate that increases and slows appropriately and is comparable to that of a normal sinus response in relation to the level of activity, while receiving no therapy or therapy with AV nodal-blocking drugs, can participate in all competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ). The use of beta-blockers is prohibited in some competitive sports. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Athletes who have atrial fibrillation in the presence of structural heart disease who maintain a ventricular rate comparable to that of an appropriate sinus tachycardia during physical activity while receiving no therapy or therapy with AV nodal-blocking drugs can participate in sports consistent with the limitations of the structural heart disease (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes who require anticoagulation should not participate in sports with danger of bodily collision (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes without structural heart disease who have elimination of atrial fibrillation by an ablation technique, including surgery, may participate in all competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) after four to six weeks without a recurrence or after an electrophysiologic study has confirmed non-inducibility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ATRIAL TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia may be due to an automatic focus or reentry; these arrhythmias are not commonly seen in athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"     \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with sinus node re-entry, inappropriate sinus tachycardia, or atrial tachycardia in the absence of structural heart disease who maintain a ventricular rate that increases and slows appropriately and is comparable to that of a normal sinus response in relation to the level of activity, with or without therapy, can participate in all competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with underlying structural heart disease can participate only in competitive sports consistent with the limitations of the heart disease (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes without structural heart disease who have elimination of the atrial tachyarrhythmia by an ablation technique, including surgery, may participate in all competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) after two to four weeks without a recurrence or in several days after an electrophysiologic study showing non-inducibility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular nodal reentrant tachycardia (AVNRT) is a common arrhythmia in young athletes and is often associated with symptoms resulting from a rapid heart rate. The diagnosis is usually established by obtaining a 12 lead ECG during the tachycardia. However, in some patients with brief episodes of paroxysmal arrhythmia, the diagnosis can be established with an ambulatory monitor, while exercise testing may induce the arrhythmia in others. If the diagnosis cannot be made with certainty, electrophysiologic testing may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes without structural heart disease who are asymptomatic and have AVNRT reproducibly provoked by exercise in whom prevention of the arrhythmia by therapy has been demonstrated by appropriate testing can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Athletes who do not have exercise-induced AVNRT but who experience sporadic recurrences can participate in all sports after an adequate response to therapy has been demonstrated. Asymptomatic patients who have brief and self limited episodes that do not increase in duration during exercise can participate in all sports.",
"     </li>",
"     <li>",
"      Athletes who have syncope, presyncope, palpitations, or other manifestations of hemodynamic impairment secondary to the AVNRT or who have structural heart disease in addition to the arrhythmia should not participate in any competitive sports until they have been adequately treated and have had no recurrences for two to four weeks. After the procedure, participation in competitive sports is permitted, with the limitations of the associated structural heart disease, if present (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes without structural heart disease who undergo successful catheter or surgical ablation who are asymptomatic and have no inducible AVNRT on follow-up electrophysiologic testing or no recurrence of arrhythmia for two to four weeks after the procedure can participate in all competitive sports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WOLFF-PARKINSON-WHITE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Wolff-Parkinson-White (WPW) pattern manifest ventricular preexcitation on the surface ECG. When this pattern is associated with documented tachycardia or symptoms referable to tachycardia, the patient is said to have the WPW syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common arrhythmia occurring in patients with WPW is an atrioventricular reentrant tachycardia (AVRT). It may have a narrow QRS complex when ventricular activation or antegrade conduction is via the normal AV node-His Purkinje system (orthodromic AVRT); or, less commonly, a wide QRS complex when ventricular activation is via the accessory pathway (antidromic AVRT). It should be noted, however, that a wide complex tachycardia with an orthodromic AVRT may be observed if there is aberrant conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sudden cardiac death due to ventricular fibrillation in patients with WPW is rare. This complication appears to be confined to patients with AF or atrial flutter and rapid conduction to the ventricles over a bypass tract which has a particularly short functional refractory period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to asymptomatic athletes with a WPW ECG pattern who have no history of palpitations or tachycardia and no evidence of structural heart disease is uncertain. Some feel that further evaluation is not necessary in such individuals. However, because of the cardiovascular demands of high intensity sports, others feel that selected athletes should undergo esophageal pacing studies to induce AF or invasive electrophysiologic testing to characterize the bypass tract properties and establish the presence of a tract that has a short refractory period. Electrophysiologic testing is ideally performed with the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    . If such a pathway is found to conduct very rapidly antegrade, radiofrequency catheter ablation should be considered, even in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7,13,14,16\">",
"     7,13,14,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with ventricular preexcitation on the ECG and symptoms of palpitations, presyncope, or syncope, or with documented arrhythmia (ie, WPW syndrome) should undergo invasive electrophysiologic testing to assess both the refractory period of the accessory connection and the shortest and mean RR interval during sustained preexcited AF (",
"    <a class=\"graphic graphic_table graphicRef51644 \" href=\"UTD.htm?8/9/8348\">",
"     table 1",
"    </a>",
"    ). If the ventricular rate during preexcited AF is &ge;240",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    the athlete should be offered radiofrequency catheter ablation of the tract. Some clinicians feel that all athletes with the WPW syndrome should have catheter ablation or pharmacologic therapy regardless of the conduction characteristics of the bypass tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes without structural heart disease, without a history of palpitations, or without tachycardia (particularly those &gt;20 to 25 years old) can participate in all competitive sports. However, in younger age groups, a more in-depth evaluation including an electrophysiologic study may be recommended before allowing participation in moderate- to high-intensity competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with episodes of AV reciprocating tachycardia should be treated as previously recommended. However, it should be appreciated that they can develop atrial fibrillation with rapid ventricular rates. Electrical induction of atrial fibrillation to determine the shortest QRS interval between two complexes conducted over the accessory pathway during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      administration or exercise is recommended. Those athletes in whom the shortest cycle length is less than 250 ms should undergo ablation of the accessory pathway.",
"     </li>",
"     <li>",
"      Athletes with episodes of atrial",
"      <span class=\"nowrap\">",
"       flutter/fibrillation",
"      </span>",
"      and syncope or near syncope whose maximal ventricular rate at rest (without therapy) as a result of conduction over the accessory pathway &gt;240",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      should be considered for catheter ablation therapy of the accessory pathway prior to continuing competition. Those whose ventricular rate during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      administration is &lt;240",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      and who have no episodes of syncope or near syncope appear to be at low risk for sudden cardiac death.",
"     </li>",
"     <li>",
"      Athletes with no structural heart disease who have had successful catheter or surgical ablation of the accessory pathway, are asymptomatic, and have normal AV conduction and no inducible arrhythmia by follow-up electrophysiologic study can participate in all competitive sports after two weeks (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ). Those without an electrophysiologic study and no spontaneous recurrence of tachycardia for two to four weeks after ablation can participate in all competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VENTRICULAR PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) are common in athletes of all age groups and occur in those with or without structural heart disease. Their presence, regardless of frequency, is",
"    <strong>",
"     not",
"    </strong>",
"    a risk factor for a sustained ventricular tachyarrhythmia or sudden death, but their prognostic importance is based upon the possible association with underlying structural heart disease. Exclusion of underlying cardiac disease is the first step in these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive evaluation includes a 12 lead ECG and, in selected athletes, 24-hour ambulatory monitoring to assess the frequency and complexity of the VPBs. If there is suspicion of structural heart disease, an echocardiogram and exercise test are indicated. An increase in the frequency or complexity of VPBs during exercise may prompt further evaluation, even if there is no evidence for structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/16\">",
"     16",
"    </a>",
"    ]. In some athletes, cardiac catheterization and angiography may reveal abnormalities that have not been previously detected, including occult coronary artery disease, coronary artery abnormalities, arrhythmogenic right ventricular cardiomyopathy, a cardiac tumor, or evidence of a cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with VPBs who do not have structural heart disease do not appear to have an increased risk of cardiovascular events. This was suggested by a study of 355 competitive athletes (only 26 with structural heart disease) who had undergone ambulatory monitoring because of palpitations, VPBs on a resting 12 lead ECG, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/17\">",
"     17",
"    </a>",
"    ]. Seventy-one of these athletes had frequent VPBs, defined as &ge;2000 VPBs in 24 hours, with or without NSVT.",
"   </p>",
"   <p>",
"    One patient with frequent VPBs and NSVT, who had structural heart disease, died suddenly. The 70 surviving patients with frequent VPBs underwent a program of deconditioning (three months without participation in competitive sports) followed by repeated ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/18\">",
"     18",
"    </a>",
"    ]. Among these patients, 16 had complete resolution of VPBs, 34 had partial resolution (&lt;500 VPBs and no NSVT), and 20 had no change. There were no subsequent deaths or cardiovascular events in a mean of eight years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes without structural heart disease who have premature ventricular complexes at rest and during exercise, and exercise testing (comparable to the sport in which they compete) can participate in all competitive sports. Should the premature ventricular complexes increase in frequency during exercise or exercise testing to the extent that they produce symptoms of impaired consciousness, significant fatigue, or dyspnea, the athlete should be periodically evaluated and can participate in class IA competitive sports only (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with structural heart disease who are in high-risk groups and have premature ventricular complexes (with or without treatment) can participate in class IA competitive sports only (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ). Such athletes with premature ventricular complexes that are suppressed by drug therapy (as assessed by ambulatory ECG recordings) during participation in the sport can compete in only class IA competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most otherwise fit individuals who present with sustained or nonsustained symptomatic monomorphic or polymorphic ventricular tachycardia have underlying structural heart disease. Since these arrhythmias are potentially life-threatening, further evaluation is essential and includes a 12 lead ECG, 24-hour ambulatory monitoring, exercise testing, echocardiography, cardiac magnetic resonance, cardiac catheterization, and electrophysiologic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference recommendations for determining the eligibility for competition in athletes with cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with a structurally normal heart and monomorphic nonsustained or sustained VT that can be localized to a specific site(s) in the heart are candidates for a catheter ablation procedure that may potentially offer a cure. Following a successful ablation procedure, the athlete can resume full competitive activity within two to four weeks if there is subsequent failure to induce VT during electrophysiologic study (EPS)",
"      <span class=\"nowrap\">",
"       with/without",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      when the VT was reproducibly induced before ablation.",
"     </li>",
"     <li>",
"      A more conservative approach is recommended for the athlete who chooses drug suppression because catecholamines released during athletic activity can counter the suppressive effects of the drug, and the VT can re-emerge. In this setting, the athlete should generally not compete in any sports for at least two to three months after the last VT episode.",
"      <br/>",
"      <br/>",
"      If there have been no clinical recurrences, the VT is not inducible by exercise, exercise testing, or EPS, and the athlete has no structural heart disease, all competitive sports may be permitted. Because deconditioning can result in the loss or lessening of ventricular arrhythmias, a short period of deconditioning and retesting can be considered in some athletes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"       \"Nonsustained VT in the absence of apparent structural heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the athlete with structural heart disease and VT, moderate- and high-intensity competition is contraindicated regardless of whether the VT is suppressed or ablated. Only class IA competitive sports are permitted (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An exception to this general recommendation is the asymptomatic athlete with brief (generally &lt;8 to 10 consecutive ventricular beats) episodes of nonsustained monomorphic VT, rates generally &lt;150",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      and no structural heart disease established by noninvasive and invasive tests. These athletes do not appear to be at increased risk for sudden cardiac death. If exercise testing (preferably by ambulatory ECG recording during the specific competitive activity) demonstrates suppression of the VT or no significant worsening compared with baseline, participation in all competitive sports is permissible (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The desire of the athlete to continue athletic competition should not represent the primary indication for use of an implantable cardioverter-defibrillator (ICD). The efficacy with which these devices will terminate a potentially lethal arrhythmia under the extreme conditions of competitive sports, with the associated metabolic and autonomic changes, and possible myocardial ischemia, is unknown. In addition, sports with physical contact may result in damage to the ICD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lead, preventing normal function. For athletes with ICDs, all moderate and high intensity sports are contraindicated. Class IA sports are permitted (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     VENTRICULAR FLUTTER AND FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with conditions that result in cardiac arrest in the presence or absence of structural heart disease generally are treated with an ICD and cannot participate in any moderate- or high-intensity competitive sports (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]. However, athletes with ICDs and who have had no episodes of ventricular flutter or ventricular fibrillation requiring device therapy for six months may engage in class IA competitive sports. Recommendations in the section on VT also apply. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CONGENITAL LONG QT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the long QT syndrome (LQTS) may be complex and difficult in some patients. Although a corrected QT interval of 440 to 450 ms has been used as the upper limit of normal, a diagnosis of LQTS should be based not only on the corrected QT interval, but also on a history of symptoms, family history, and typical ECG changes (abnormal T waves and T wave alternans) (",
"    <a class=\"graphic graphic_table graphicRef50091 \" href=\"UTD.htm?31/23/32124\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with a LQTS are at risk for sudden death with activity and should be restricted from all competitive sports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS AND PACEMAKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with an implantable cardioverter-defibrillator (ICD) or antitachycardia pacemaker are restricted from all moderate and high intensity sports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]. Low intensity competitive sports that do not constitute a significant risk of trauma to the ICD or the leads are contraindicated for at least six months after the last episode of the clinical arrhythmia that required intervention. Thereafter, athletes can participate in low intensity competitive sports only. Any sport in which there is a risk of traumatic injury to the device or lead system is contraindicated (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Furthermore, athletes with an ICD should undergo exercise testing if there is a history of AF with a potentially rapid ventricular rate, a need for low tachyarrhythmia detection rates, or the potential to raise the sinus rate to near the ICD tachyarrhythmia detection level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with permanent pacemakers have identical restrictions on sports with danger of traumatic injury, especially if they are pacemaker-dependent. Exercise testing may be required to ensure that the pacemaker's upper-rate limit, upper-rate behavior, rate responsiveness, and type of activity sensor are appropriate for the athlete's specific sport. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 36th Bethesda Conference recommended that athletes with pacemakers should not engage in sports with a danger of bodily collision because such trauma may damage the pacemaker system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"     7",
"    </a>",
"    ]. This restriction should clearly exclude activities where direct blows to the chest are a part of the sport, such as football, rugby, boxing, martial arts, hockey, and lacrosse. Protective padding for the device is advisable for other sports such as soccer, basketball, baseball, and softball where trauma is possible but less likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3441095\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmias are not infrequently documented in athletes and can be a source of morbidity and mortality, particularly ventricular tachyarrhythmias leading to sudden cardiac death (SCD). The most important part of the evaluation of arrhythmias in athletes is to identify those with life-threatening arrhythmias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      underlying structural heart disease which puts them at risk for arrhythmias. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Syncope in athletes is most commonly related to neurally mediated causes or volume depletion following exercise. However, structural heart diseases such as hypertrophic cardiomyopathy and aortic stenosis may be potentially life-threatening causes of syncope in athletes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Syncope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus bradycardia and sinus tachycardia that are appropriate for the clinical situation are not considered abnormal, and no further testing or therapy is necessary. Atrial premature beats are common in the general population and in athletes, and they are not generally associated with underlying structural heart disease or symptoms. Except for a 12 lead ECG, no further evaluation is necessary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sinus and AV node dysfunction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Atrial or junctional premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sustained atrial fibrillation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atrial flutter are uncommon in athletes. A full cardiac evaluation, including echocardiogram, should be performed for any patient (athlete or not) with one of these arrhythmias. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Atrial flutter'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia (AVNRT) is a common arrhythmia in young athletes and is often associated with symptoms resulting from a rapid heart rate. The diagnosis is usually established by obtaining a 12 lead ECG during the tachycardia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Atrioventricular nodal reentrant tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Wolff-Parkinson-White (WPW) pattern manifest ventricular preexcitation on the surface ECG. When this pattern is associated with documented tachycardia or symptoms referable to tachycardia, the patient is said to have the WPW syndrome. The most common arrhythmia occurring in patients with WPW is an atrioventricular reentrant tachycardia (AVRT), although atrial fibrillation and other arrhythmias may arise. Athletes with ventricular preexcitation on the ECG and symptoms of palpitations, presyncope, or syncope, or with documented arrhythmia (ie, WPW syndrome) should undergo invasive electrophysiologic testing for both diagnostic and potential therapeutic (ie, catheter ablation of the accessory pathway) purposes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Wolff-Parkinson-White syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular premature beats (VPBs) are common in athletes of all age groups and occur in those with or without structural heart disease. Their presence, regardless of frequency, is",
"      <strong>",
"       not",
"      </strong>",
"      a risk factor for a sustained ventricular tachyarrhythmia or sudden death, but their prognostic importance is based upon an association with underlying structural heart disease. Noninvasive evaluation includes a 12 lead ECG and, in selected athletes, 24-hour ambulatory monitoring to assess the frequency and complexity of the VPBs. If there is suspicion of structural heart disease, an echocardiogram and exercise test are indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ventricular premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most otherwise fit individuals who present with sustained or nonsustained symptomatic monomorphic or polymorphic ventricular tachycardia have underlying structural heart disease. Since these arrhythmias are potentially life-threatening, further evaluation is essential and includes a 12 lead ECG, 24-hour ambulatory monitoring, exercise testing, and echocardiography or cardiac magnetic resonance along with cardiac catheterization and electrophysiologic testing in select patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Athletes with congenital long QT syndrome are at risk for sudden death with activity and should be restricted from all competitive sports. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H13#H13\">",
"       \"Prognosis and management of congenital long QT syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recommendations regarding the ability to participate in competitive athletics or intense athletic training are discussed in the relevant sections above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198975982\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Drs. David Bharucha and Roger Marinchak, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/1\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/2\">",
"      Sakaguchi S, Shultz JJ, Remole SC, et al. Syncope associated with exercise, a manifestation of neurally mediated syncope. Am J Cardiol 1995; 75:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/3\">",
"      Colivicchi F, Ammirati F, Biffi A, et al. Exercise-related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome. Eur Heart J 2002; 23:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/4\">",
"      Colivicchi F, Ammirati F, Santini M. Epidemiology and prognostic implications of syncope in young competing athletes. Eur Heart J 2004; 25:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/5\">",
"      Calkins H, Seifert M, Morady F. Clinical presentation and long-term follow-up of athletes with exercise-induced vasodepressor syncope. Am Heart J 1995; 129:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/6\">",
"      Hastings JL, Levine BD. Syncope in the athletic patient. Prog Cardiovasc Dis 2012; 54:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/7\">",
"      Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Task Force 7: arrhythmias. J Am Coll Cardiol 2005; 45:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/8\">",
"      Talan DA, Bauernfeind RA, Ashley WW, et al. Twenty-four hour continuous ECG recordings in long-distance runners. Chest 1982; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/9\">",
"      Abdon NJ, Landin K, Johansson BW. Athlete's bradycardia as an embolising disorder? Symptomatic arrhythmias in patients aged less than 50 years. Br Heart J 1984; 52:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/10\">",
"      Stein R, Medeiros CM, Rosito GA, et al. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol 2002; 39:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/11\">",
"      Bj&oslash;rnstad H, Storstein L, Meen HD, Hals O. Ambulatory electrocardiographic findings in top athletes, athletic students and control subjects. Cardiology 1994; 84:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/12\">",
"      Wang YG, Mariman RJ, Wilbur DJ, et al. Various electrocardiographic and electrophysiologic presentations of normal and abnormal sinus node. J Cardiovasc Electrophysiol 1992; 3:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/13\">",
"      Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993; 87:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/14\">",
"      Furlanello F, Bertoldi A, Bettini R, et al. Life-threatening tachyarrhythmias in athletes. Pacing Clin Electrophysiol 1992; 15:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/15\">",
"      Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assessment of asymptomatic patients with the Wolff-Parkinson-White electrocardiographic pattern. N Engl J Med 1989; 320:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/16\">",
"      Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac arrhythmias in athletes: clinical relevance and prognostic importance. Am Heart J 1990; 119:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/17\">",
"      Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 2002; 40:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23192/abstract/18\">",
"      Biffi A, Maron BJ, Verdile L, et al. Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 2004; 44:1053.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 990 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23192=[""].join("\n");
var outline_f22_41_23192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3441095\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SINUS AND AV NODE DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ATRIAL OR JUNCTIONAL PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_41_23193="Fibrinolytic markers and cardiovascular risk";
var content_f22_41_23193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrinolytic markers and cardiovascular risk",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23193/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/41/23193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma concentrations of fibrinogen appear to be an independent predictor of initial and recurrent cardiovascular events. There is also increasing evidence that markers of impaired fibrinolysis are associated with both the development of coronary heart disease (CHD) and, in patients with CHD, an increased number of coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atherosclerotic plaque rupture and erosions are recognized precipitants of thrombosis and lead to an acute ischemic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The thrombotic response to vascular injury is influenced by a variety of factors, including the thrombogenicity of the vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/5\">",
"     5",
"    </a>",
"    ], platelet deposition, local blood flow (which is influenced by rheologic properties) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and the effectiveness of protective fibrinolytic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic activity is regulated by a balance between plasminogen activators, such as tissue-type plasminogen activator (t-PA), and inhibitors, such as plasminogen activator inhibitor type 1 (PAI-1), alpha-2-antiplasmin, and lipoprotein (a). PAI-1 is a major determinant of the resistance of platelet-rich arterial thrombi to thrombolysis as it binds to and inactivates both t-PA and urokinase-type plasminogen activator [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decreased fibrinolytic activity is characterized by prolonged clot lysis times and elevated plasma concentrations of PAI-1 and t-PA antigen. Circulating t-PA antigen consists mainly of",
"    <span class=\"nowrap\">",
"     t-PA/PAI-1",
"    </span>",
"    complexes and lesser amounts of free t-PA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Tests for fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinolytic activity demonstrates circadian variability. Among patients with stable coronary heart disease, PAI-1 activity peaks in the early morning while t-PA activity is at its nadir [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/13\">",
"     13",
"    </a>",
"    ]. This correlates with the circadian pattern of acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .) Treatment with a beta blocker ameliorated this relatively prothrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasminogen activator inhibitor type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAI-1 is synthesized by endothelium and smooth muscle cells in normal and atherosclerotic arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. PAI-1 synthesis is regulated by a number of cytokines, including platelet-derived growth factor, thrombin, interleukin-1, transforming growth factor-beta, basic fibroblast growth factor, angiotensin II, and endotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Smooth muscle cells are major regulators of the fibrinolytic potential within the vessel wall; as a result, they influence the thrombotic response following endothelial disruption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The human PAI-1 gene is located on chromosome 7 and polymorphism in the promoter region of the PAI-1 gene has been identified; it is characterized by a \"deletion\" allele with a sequence of four guanosines (4G) and an \"insertion\" allele with five guanosines (5G) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study, subjects who were homozygous for the 4G allele had levels of PAI-1 that were 30 percent higher than those who are homozygous for the 5G allele [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/20\">",
"     20",
"    </a>",
"    ]. Additionally, overexpression of the PAI-1 gene has been detected in the intima of human atherosclerosis arteries and specifically localized to smooth muscle cells and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The putative involvement of elevated PAI-1 activity in atherothrombosis may reflect two processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased PAI-1 expression following plaque rupture or endothelial erosion may permit fibrin to persist on the surface of the injured vessel.",
"     </li>",
"     <li>",
"      Incorporation of fibrin into the vessel wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FIBRINOLYSIS AND CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between fibrinolytic activity and CHD has been evaluated in patients with and without CHD. In patients with CHD, coronary atheromatous plaque burden, established with angiography, and smoking are associated with reduced acute local fibrinolytic activity of the heart due to both impaired acute release of t-PA and increased PAI-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In other reports, elevated PAI-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged clot lysis times appear to be predictive of unstable angina and myocardial infarction in patients with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/23-29\">",
"     23-29",
"    </a>",
"    ], restenosis following percutaneous angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/30\">",
"     30",
"    </a>",
"    ], and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study of 71 patients with myocardial infarction before age 45, for example, t-PA activity measured after venous occlusion was significantly reduced compared to 50 age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/27\">",
"     27",
"    </a>",
"    ]. The low t-PA activity was due to high plasma levels of PAI-1 and, to a lesser degree, impaired release of t-PA from the vessel wall.",
"   </p>",
"   <p>",
"    The European Concerted Action on Thrombosis (ECAT) Angina Pectoris study evaluated 3043 patients with angina pectoris who were followed for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/26\">",
"     26",
"    </a>",
"    ]. High levels of PAI-1 antigen, PAI-1 activity, t-PA antigen, and t-PA activity after venous occlusion were associated with an increased risk of coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the associations of risk with PAI-1 antigen and PAI-1 activity risk disappeared after adjustment for parameters reflecting insulin resistance.",
"   </p>",
"   <p>",
"    In patients admitted with acute coronary syndromes, systemic measurements may not correlate with endothelial fibrinolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/29\">",
"     29",
"    </a>",
"    ]. In one study of patients with acute coronary syndromes, elevations in t-PA antigen and PAI-1 (compared to patients with stable angina) were seen at presentation and 10 days. In comparison, endothelial t-PA release was transiently reduced, returning to the values seen in patients with stable angina by 10 days. These observations suggest reduced endothelial fibrinolytic activity correlates more to intracoronary thrombus formation than to steady state concentrations of fibrinolytic markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predicting the development of CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to the preceding observations in patients with CHD, population-based studies have demonstrated an inconsistent relationship between fibrinolytic parameters and predicting the development of CHD. The range of conflicting data can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low systemic fibrinolytic activity, as measured by the dilute clot lysis time, was a predictor of CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After adjustment for traditional risk factors, particularly HDL-cholesterol, tissue plasminogen activator (t-PA) antigen has not been a risk factor for future CHD or myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The association of circulating t-PA antigen with the risk of a first-ever nonfatal myocardial infarction or death from CHD was investigated in a 1925 cases and 3616-controls within the prospective population-based Reykjavik Study, which had a median follow-up of 19.4 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/22\">",
"       22",
"      </a>",
"      ]. For every one standard deviation increase, the age and sex-adjusted odds ratio for coronary heart disease was 1.25 (1.18, 1.33). However, after further adjustment for conventional cardiovascular risk factors, the odds ratio was 1.07 (0.99, 1.14) for t-PA antigen. In a meta-analysis that included the Reykjavik Study with 21 prospective studies (13 with t-PA antigen), adjusted risk ratio per one SD higher baseline level of t-PA antigen (5494 CHD cases) was 1.13 (1.06, 1.21).",
"     </li>",
"     <li>",
"      There are conflicting data as to whether PAI-1 activity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/34,35\">",
"       34,35",
"      </a>",
"      ] or specific polymorphisms of the PAI-1 gene locus have predictive value [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lack of an important association between genetic variations of several fibrinolytic and coagulation proteins and the risk of a myocardial infarction was also shown by a pooled analysis of six studies involving 3395 patients and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/38\">",
"       38",
"      </a>",
"      ]. There was no association with genetic variations of factor V Leiden or prothrombin mutations and only a weak association with fibrinogen or PAI-1 polymorphisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Familial risk of CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between PAI-1 activity and familial risk of premature CHD has been evaluated in several case-control series, but the findings have been inconsistent. In different studies, PAI-1 concentrations in offspring of patients with myocardial infarction have been higher than in controls without such a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/39\">",
"     39",
"    </a>",
"    ] or similar to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, a family history of CHD was associated with homozygosity for the 4G allele [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Relationship to cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relationship between the PAI-1 genotype and CHD is uncertain, there may be an association with the risk of cerebrovascular mortality in women. In one study of 12,239 women, aged 52 to 67, who were followed for 18 years, 4G4G homozygotes had a significantly reduced risk of cerebrovascular mortality when compared to 5G5G homozygotes (relative risk 0.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/42\">",
"     42",
"    </a>",
"    ]. When compared to 5G5G homozygotes, the relative risk of cerebrovascular mortality in 4G5G heterozygotes was 0.7.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Relationship to hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is an established risk factor for cardiovascular disease, especially myocardial infarction and stroke, which are thrombotic complications. It is thus possible that hypertension may exert its effect, in part, through the promotion of a prothrombotic state. The association between impaired fibrinolysis and blood pressure was examined in the Framingham offspring population, which included 2652 men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/43\">",
"     43",
"    </a>",
"    ]. In both sexes, the levels of PAI-1 and t-PA antigen were positively correlated with systolic and diastolic blood pressure (p&lt;0.001). Plasma viscosity was associated with systolic and diastolic blood pressure in women only. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FIBRINOLYSIS AND THE INSULIN RESISTANCE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance has been associated with obesity, hypertension, dyslipidemia, and type 2 diabetes. This constellation of findings is called the insulin resistance syndrome, the metabolic syndrome, or syndrome X. Patients with insulin resistance are at increased risk of developing cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired fibrinolytic capacity is common in patients with the insulin resistance syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/44-51\">",
"     44-51",
"    </a>",
"    ]. The following reports illustrate the range of findings, and suggest that the increase in cardiovascular risk seen with insulin resistance is due at least in part to impaired fibrinolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis from the Framingham Offspring Study, fasting insulin levels and levels of hemostatic factors were measured in 2962 patients (80 percent with normal glucose tolerance and 20 percent with glucose intolerance or diabetes). Levels of PAI-1 and tPA antigen were significantly higher among patients with glucose intolerance than among those with normal glucose tolerance. In both groups of patients, levels of PAI-1 and tPA antigen increased significantly across quintiles of fasting insulin concentration.",
"     </li>",
"     <li>",
"      The relationship between fibrinolytic markers and the insulin resistance syndrome was also examined in 1484 patients with angina pectoris as part of the ECAT Angina Pectoris study [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/45\">",
"       45",
"      </a>",
"      ]. Fasting serum insulin correlated with PAI-1 activity, PAI-1 antigen, and t-PA antigen. This correlation decreased after adjustment for other elements of the insulin resistance syndrome (primarily body mass index and triglycerides).",
"     </li>",
"     <li>",
"      In a cross-sectional study of 1276 patients of South Asian, Chinese, European, and Native Indian ancestry, those with the metabolic syndrome had significantly higher levels of PAI-1 (24.2 versus 14.6",
"      <span class=\"nowrap\">",
"       U/mL),",
"      </span>",
"      significantly more atherosclerosis (maximum intimal medial thickness 0.78 versus 0.74) and a higher prevalence of cardiovascular disease (17 versus 7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients with the metabolic syndrome had an increased risk of cardiovascular disease, which remained significant after adjustment for carotid intimal-medial thickness, age, sex, and smoking. However, the increase in risk was no longer significant after adjustment for PAI-1 levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The individual components of the insulin resistance syndrome increase the expression of PAI-1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin and insulin-like growth factor-1 (IGF-1) increase PAI-1 mRNA levels [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. In addition, glucose, with or without insulin, increases PAI-1 mRNA and PAI-1 secretion in endothelial cells, suggesting that the increase in PAI-1 associated with type 2 diabetes may be partly due to hyperglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/54\">",
"       54",
"      </a>",
"      ]. However, a major role of hyperglycemia is unlikely since PAI-1 levels are normal in patients with type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity can also induce expression and secretion of PAI-1. Obese patients have significantly higher adipose tissue PAI-1 mRNA levels and plasma PAI-1 protein levels than nonobese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/57\">",
"       57",
"      </a>",
"      ]. Selected cytokines expressed in adipose tissue increase the production of PAI-1, including transforming growth factor beta 1 (TGF beta 1), tumor necrosis factor alpha (TNF alpha), and interleukin 1 beta (IL 1 beta) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/14,58\">",
"       14,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertriglyceridemia reflects the accumulation of triglyceride-rich lipoproteins, including VLDL, in plasma. VLDL induces overexpression of PAI-1 mRNA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/53\">",
"       53",
"      </a>",
"      ] and increases PAI-1 release by endothelial and HepG2 cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obese patients have increased levels of angiotensinogen compared to nonobese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/61\">",
"       61",
"      </a>",
"      ] and adipocytes from obese individuals secrete more angiotensinogen [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/62\">",
"       62",
"      </a>",
"      ]. Several metabolites of angiotensinogen (angiotensin II, III and IV) induce PAI-1 expression and release via the AT-1 receptor on adipocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FIBRINOLYSIS AND HYPERLIPOPROTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association has been noted between impaired fibrinolysis and certain lipoproteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Triglycerides and VLDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma triglycerides and very low density lipoprotein (VLDL) have been positively correlated with PAI-1 antigen, PAI-1 activity, and t-PA antigen, and negatively correlated with t-PA activity activation measured after venous occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/60,64\">",
"     60,64",
"    </a>",
"    ]. In one report, lowering plasma triglycerides by 20 percent or more with a low-carbohydrate diet in hypertriglyceridemic subjects was associated with a 40 percent reduction in PAI-1 antigen levels (p&lt;0.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The latter observation suggests that triglycerides or VLDL might increase PAI-1 release. In vitro studies are compatible with this hypothesis as VLDL causes a dose-dependent release of PAI-1 from endothelial and hepatic (HepG2) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. This effect is mediated by an interaction with the LDL receptor that involves overexpression of the stable 2.2 kb PAI-1 mRNA with a minor effect on the 3.2 kb PAI-1 mRNA transcript [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/53\">",
"     53",
"    </a>",
"    ]. VLDL induces transcription of the VLDL response element (VLDLRE) located at residues -672 to -657 in the promoter region of the human PAI-1 gene; this activity is influenced by the",
"    <span class=\"nowrap\">",
"     4G/5G",
"    </span>",
"    polymorphism, which is adjacent to the binding site of the VLDLRE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The release of t-PA from endothelial cells is suppressed by LDL, Lp(a), and HDL in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, LDL and acetylated LDL can stimulate PAI-1 release, an effect that is not dependent upon an interaction with the LDL receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/67\">",
"     67",
"    </a>",
"    ]. These actions of LDL may partly explain the finding in an epidemiologic study that hyperlipidemia is associated with an imbalance of coagulation over fibrinolysis, as measured by molecular markers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lipoprotein(a)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lp(a) may interfere with fibrinolysis by competing with plasminogen binding to plasminogen receptors, fibrinogen, fibrin, and t-PA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The interference with plasminogen binding is mediated by the fourth kringle of the apoprotein (a) component of Lp(a), which is homologous with the fibrin-binding domain of plasminogen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/72\">",
"     72",
"    </a>",
"    ]. Other antifibrinolytic properties of Lp(a) include impaired activation of plasminogen by t-PA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/71\">",
"     71",
"    </a>",
"    ] and induction of PAI-1 synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/73\">",
"     73",
"    </a>",
"    ]. However, these in vitro findings have yet to be tested in observational and interventional studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACHES TO IMPAIRED FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapies for patients at increased risk for CHD are also effective in those with impaired fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in diet can improve fibrinolytic activity. PAI-1 levels can be reduced by a low carbohydrate diet in hypertriglyceridemic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/60\">",
"     60",
"    </a>",
"    ] and by a hypocaloric diet in overweight individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. As an example, the effect of diet, with or without exercise, on fibrinolysis was evaluated in 121 healthy overweight postmenopausal women who were randomized to 12 weeks of a reduced caloric diet only, a reduced caloric diet plus exercise (aerobic and anaerobic for 1 to 1.5 hours three times per week), or no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/76\">",
"     76",
"    </a>",
"    ]. At baseline, PAI-1 activity, PAI-1 antigen, and t-PA antigen correlated with waist-to-hip ratio,",
"    <span class=\"nowrap\">",
"     abdominal/total",
"    </span>",
"    fat tissue mass, systolic blood pressure, fasting blood glucose, and serum triglycerides. After 12 weeks, diet alone lowered PAI-1 activity by 46 percent, PAI-1 antigen by 36 percent, and t-PA antigen by 29 percent compared with no intervention. Exercise conferred no additional benefit. At six months, there was no significant change in fibrinolysis despite maintenance of an 8 kg weight loss.",
"   </p>",
"   <p>",
"    Thus, fibrinolysis can be transiently improved by an energy-restrictive diet, but cannot be maintained by continued weight loss. Neither PAI-1 nor t-PA activity appear to be affected by fish oils or polyunsaturated corn oil [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolysis can be improved by moderate alcohol intake (three to seven drinks per week), which may contribute to the cardiovascular benefit of alcohol. The Framingham Offspring study found that moderate alcohol intake was associated with lower levels of fibrinogen, von Willebrand factor, plasma viscosity, and factor VII [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/78\">",
"     78",
"    </a>",
"    ]. In contrast, a higher intake of alcohol (7 to 21 drinks per week) was associated with impaired fibrinolytic potential. There was no relationship between these effects and beverage type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H19#H19\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Antithrombotic effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aerobic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional studies have shown that PAI-1 levels are inversely correlated with physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/79\">",
"     79",
"    </a>",
"    ]. Furthermore, physical training improves fibrinolysis by lowering PAI-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]; the benefit of exercise is seen primarily in homozygotes for the 4G allele who have elevated PAI-1 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients (usually obese) with type 2 diabetes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    improves insulin resistance and lowers the blood glucose and plasma insulin and PAI-1 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lipid-lowering drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the effect of HMG-CoA reductase inhibitors (statins) and the fibric acid derivatives on fibrinolytic activity. Statins have a significant beneficial effect on fibrinolytic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/87\">",
"     87",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     Pravastatin",
"    </a>",
"    , for example, reduces PAI-1 antigen levels by 26 to 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Similar beneficial effects have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fibric acid derivatives also have favorable effects on fibrinolytic markers. In one report, for example, 20 patients with primary (type IV) hypertriglyceridemia were randomized to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    (600 mg BID) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/94\">",
"     94",
"    </a>",
"    ]. At 12 weeks, gemfibrozil, compared to placebo, significantly reduced PAI-1 activity, and enhanced t-PA antigen release after venous occlusion. The improvement in fibrinolysis correlated with the magnitude of triglyceride lowering. In another study of 21 hyperlipidemic cardiac transplant recipients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    lowered PAI-1 concentrations by 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     ACE inhibitors/angiotensin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II can influence plasma fibrinolytic properties by inducing the release of PAI-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/96\">",
"     96",
"    </a>",
"    ]. The administration of angiotensin converting enzyme (ACE) inhibitors in patients with hypertension and diabetes or after a myocardial infarction reduces PAI-1 concentrations; this effect is independent of blood pressure reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. ACE inhibitors are more effective in those who are homozygous for the 4G allele [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/99\">",
"     99",
"    </a>",
"    ]. Whether this contributes to the beneficial effect of these drugs in these settings is not known. Studies in patients with heart failure suggest that the angiotensin II receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    has a similar effect on PAI-1 and that both classes of drugs may increase t-PA activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between the use of estrogen replacement therapy (ERT) and fibrinolytic variables in postmenopausal women has been examined in two cross-sectional studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23193/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. However, the clinical significance of any changes that might occur is not certain. The Women's Health Initiative, mostly of primary prevention, and the HERS trials of secondary prevention showed that estrogen-progestin replacement had no cardioprotective effect and may have produced harm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired fibrinolysis is associated with an increased incidence of coronary events in patients with acute coronary syndromes. The pathophysiologic role of impaired fibrinolytic mechanisms is uncertain since the increase in risk appears to be confined to the acute phase. Population-based studies do not support impaired fibrinolytic parameters as independent predictors for the development CHD although genetic analyses of the PAI-1",
"    <span class=\"nowrap\">",
"     4G/5G",
"    </span>",
"    polymorphism may clarify these issues in future prospective studies.",
"   </p>",
"   <p>",
"    Impaired fibrinolysis is present in patients with type 2 diabetes mellitus, hyperlipidemia (especially hypertriglyceridemia), physical inactivity, and post-menopausal women. Therapies shown to improve fibrinolysis are those of benefit for CHD risk in general and include dietary modification , acute weight loss,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in type 2 diabetics, LDL-cholesterol lowering with a statin, triglyceride lowering with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , and estrogen replacement therapy.",
"   </p>",
"   <p>",
"    Until the role of PAI-1",
"    <span class=\"nowrap\">",
"     4G/5G",
"    </span>",
"    polymorphisms and other genetic determinants of fibrinolysis are clarified, measurement of fibrinolytic parameters as part of the risk evaluation for coronary heart disease is",
"    <strong>",
"     not",
"    </strong>",
"    warranted.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/1\">",
"      Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/2\">",
"      Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/3\">",
"      Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/4\">",
"      Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/5\">",
"      Fern&aacute;ndez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/6\">",
"      Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/7\">",
"      Rosenson RS. Viscosity and ischemic heart disease. J Vasc Med Biol 1993; 4:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/8\">",
"      Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89:6998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/9\">",
"      Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/10\">",
"      Chomiki N, Henry M, Alessi MC, et al. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/11\">",
"      Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/12\">",
"      Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/13\">",
"      Sayer JW, Gutteridge C, Syndercombe-Court D, et al. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998; 32:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/14\">",
"      Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/15\">",
"      Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/16\">",
"      Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266:9419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/17\">",
"      Wojta J, Gallicchio M, Zoellner H, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993; 70:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/18\">",
"      Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/19\">",
"      Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995; 74:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/20\">",
"      Humphries SE, Panahloo A, Montgomery HE, et al. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/21\">",
"      Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/22\">",
"      Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013; 8:e55175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/23\">",
"      Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/24\">",
"      Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/25\">",
"      Zalewski A, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates. Circulation 1991; 83:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/26\">",
"      Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/27\">",
"      Hamsten A, Wiman B, de Faire U, Blomb&auml;ck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/28\">",
"      Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/29\">",
"      Hoffmeister HM, Jur M, Ruf-Lehmann M, et al. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998; 31:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/30\">",
"      Huber K, J&ouml;rg M, Probst P, et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/31\">",
"      Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/32\">",
"      Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/33\">",
"      Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/34\">",
"      Lowe GD, Yarnell JW, Sweetnam PM, et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/35\">",
"      Scarabin PY, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/36\">",
"      Gardemann A, Lohre J, Katz N, et al. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999; 82:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/37\">",
"      Anderson JL, Muhlestein JB, Habashi J, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999; 34:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/38\">",
"      Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/39\">",
"      Rallidis LS, Megalou AA, Papageorgakis NH, et al. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost 1996; 76:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/40\">",
"      Bara L, Nicaud V, Tiret L, et al. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost 1994; 71:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/41\">",
"      Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/42\">",
"      Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/43\">",
"      Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/44\">",
"      Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/45\">",
"      Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/46\">",
"      Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/47\">",
"      Eliasson M, Asplund K, Evrin PE, et al. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 1994; 43:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/48\">",
"      Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/49\">",
"      Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/50\">",
"      McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/51\">",
"      Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/52\">",
"      Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992; 267:12412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/53\">",
"      Sironi L, Mussoni L, Prati L, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/54\">",
"      Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/55\">",
"      Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/56\">",
"      Mahmoud R, Raccah D, Alessi MC, et al. Fibrinolysis in insulin-dependent diabetic patients with or without nephropathy. Fibrinolysis 1992; 6:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/57\">",
"      Eriksson P, Reynisdottir S, L&ouml;nnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/58\">",
"      Birgel M, Gottschling-Zeller H, R&ouml;hrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/59\">",
"      Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/60\">",
"      Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/61\">",
"      Umemura S, Nyui N, Tamura K, et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/62\">",
"      Engeli S, Gorzelniak K, Kreutz R, et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/63\">",
"      Skurk T, Lee YM, R&ouml;hrig K, Hauner H. Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes. Horm Metab Res 2001; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/64\">",
"      Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/65\">",
"      Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/66\">",
"      Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/67\">",
"      Tremoli E, Camera M, Maderna P, et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/68\">",
"      Lowe GD, Wood DA, Douglas JT, et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991; 65:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/69\">",
"      Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry 1991; 30:6671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/70\">",
"      Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989; 86:3847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/71\">",
"      Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/72\">",
"      McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/73\">",
"      Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/74\">",
"      Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/75\">",
"      Huisveld IA, Leen R, VdKooy K, et al. Body composition and weight reduction in relation to antigen and activity of plasminogen activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 1990; 4:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/76\">",
"      Svendsen OL, Hassager C, Christiansen C, et al. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/77\">",
"      Toft I, B&oslash;naa KH, Ingebretsen OC, et al. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol 1997; 17:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/78\">",
"      Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation 2001; 104:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/79\">",
"      Shaukat N, Douglas JT, Bennet JL, de Bono DP. Can physical activity explain the differences in insulin levels and fibrinolytic activity between young Indo-origin and European relative of patients with coronary heart disease? Fibrinolysis 1995; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/80\">",
"      Speiser W, Langer W, Pschaick A, et al. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res 1988; 51:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/81\">",
"      Estell&eacute;s A, Aznar J, Tormo G, et al. Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/82\">",
"      Gris JC, Schved JF, Feugeas O, et al. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost 1990; 64:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/83\">",
"      V&auml;is&auml;nen SB, Humphries SE, Luong LA, et al. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost 1999; 82:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/84\">",
"      Vague P, Juhan-Vague I, Alessi MC, et al. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/85\">",
"      Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/86\">",
"      Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991; 8:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/87\">",
"      Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/88\">",
"      Avellone G, Di Garbo V, Panno AV, et al. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/89\">",
"      Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/90\">",
"      Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/91\">",
"      Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/92\">",
"      Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/93\">",
"      Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/94\">",
"      Avellone G, Di Garbo V, Cordova R, et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coagul Fibrinolysis 1995; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/95\">",
"      Zambrana JL, Velasco F, Castro P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol 1997; 80:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/96\">",
"      Vaughan DE. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol 1997; 20:II.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/97\">",
"      Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/98\">",
"      Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/99\">",
"      Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002; 105:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/100\">",
"      Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/101\">",
"      Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996; 93:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23193/abstract/102\">",
"      Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91:1952.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1509 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23193=[""].join("\n");
var outline_f22_41_23193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIBRINOLYTIC ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasminogen activator inhibitor type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FIBRINOLYSIS AND CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predicting the development of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Familial risk of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Relationship to cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Relationship to hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FIBRINOLYSIS AND THE INSULIN RESISTANCE SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FIBRINOLYSIS AND HYPERLIPOPROTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Triglycerides and VLDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lipoprotein(a)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THERAPEUTIC APPROACHES TO IMPAIRED FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aerobic exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lipid-lowering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ACE inhibitors/angiotensin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=related_link\">",
"      Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_41_23194="Diagnostic approach to the patient with cirrhosis";
var content_f22_41_23194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to the patient with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/41/23194/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/41/23194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and the formation of regenerative nodules. It is generally considered to be irreversible in its advanced stages at which point the only option may be liver transplantation. However, reversal of cirrhosis (in its earlier stages) has been documented in several forms of liver disease following treatment of the underlying cause. Patients with cirrhosis are susceptible to a variety of complications and their life expectancy is markedly reduced.",
"   </p>",
"   <p>",
"    This topic will review issues related to the diagnosis of cirrhosis. An overview of the complications, prognosis, and general management issues is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis may present in a variety of ways [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may have stigmata of chronic liver disease discovered on routine physical examination (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical findings'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      They may have undergone laboratory or radiologic testing or an unrelated surgical procedure that incidentally uncovered the presence of cirrhosis",
"     </li>",
"     <li>",
"      They may present with decompensated cirrhosis, which is characterized by the presence of dramatic and life-threatening complications, such as variceal hemorrhage, ascites, spontaneous bacterial peritonitis (SBP), or hepatic encephalopathy",
"     </li>",
"     <li>",
"      Some patients never come to clinical attention. In older reviews, cirrhosis was diagnosed at autopsy in up to 30 to 40 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis found that the factors with the best ability to predict cirrhosis in adults with known or suspected liver disease included [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of ascites (likelihood ratio [LR] 7.2)",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;160,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (LR 6.3)",
"     </li>",
"     <li>",
"      Spider nevi (LR 4.3)",
"     </li>",
"     <li>",
"      Bonacini cirrhosis discriminant score greater than 7 (LR 9.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Bonacini cirrhosis discriminant score is calculated by giving points for the following parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       (x1000/mm",
"       <sup>",
"        3",
"       </sup>",
"       ):",
"      </span>",
"      &gt;340 zero points, 280 to 399 one point, 220 to 279 two points, 160 to 219 three points, 100 to 159 four points, 40 to 99 five points, and &lt;40 six points",
"     </li>",
"     <li>",
"      Alanine aminotransferase to aspartate aminotransferase",
"      <span class=\"nowrap\">",
"       (ALT/AST)",
"      </span>",
"      ratio: &gt;1.7 zero points, 1.2 to 1.7 one point, 0.6 to 1.19 two points, &lt;0.6 three points",
"     </li>",
"     <li>",
"      International normalized ratio (INR): &lt;1.1 zero points, 1.1 to 1.4 one point, &gt;1.4 two points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors associated with a low likelihood of cirrhosis included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lok index &lt;20 percent (LR 0.09)",
"     </li>",
"     <li>",
"      Platelet count of",
"      <span class=\"nowrap\">",
"       160,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or higher (LR 0.29)",
"     </li>",
"     <li>",
"      Absence of hepatomegaly (LR 0.37)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lok index is calculated using the platelet count, AST, ALT, and INR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/6\">",
"     6",
"    </a>",
"    ]. An online",
"    <a class=\"external\" href=\"file://www.haltctrial.org/cirrhosis.html\">",
"     calculator",
"    </a>",
"    is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include questioning about risk factors for chronic liver disease including a history of hepatitis, alcohol consumption, diabetes mellitus, use of illicit drugs (by injection or inhalation), transfusions, family history of liver disease, travel, and the presence of autoimmune diseases (including inflammatory bowel disease, rheumatoid arthritis and thyroid disease). The review of systems should include questioning related to fatigue, easy bruisability, lower extremity edema, fever, weight loss, diarrhea, pruritus, increasing abdominal girth, and confusion or sleep disturbance (possibly indicating encephalopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of physical findings have been described in patients with cirrhosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spider angiomata &mdash; Spider angiomata (also referred to as spider telangiectasias) are vascular lesions consisting of a central arteriole surrounded by many smaller vessels. They are most frequently found on the trunk, face, and upper limbs. The body (the central arteriole) can be seen pulsating when compressed with a glass slide. Blood fills the central arteriole first before traveling to the peripheral tips of each leg after blanching. There are usually multiple radiating \"legs\" and surrounding erythema that may encompass the entire lesion or only its central portion.",
"      <br/>",
"      <br/>",
"      While their pathogenesis is incompletely understood, they are believed to result from alterations in sex hormone metabolism. One study suggested that the presence of spider angiomata in men was associated with an increase in the",
"      <span class=\"nowrap\">",
"       estradiol/free",
"      </span>",
"      testosterone ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/7\">",
"       7",
"      </a>",
"      ]. Acquired spider angiomata are not specific for cirrhosis since they may also be seen during pregnancy (",
"      <a class=\"graphic graphic_picture graphicRef74047 \" href=\"UTD.htm?0/23/369\">",
"       picture 1",
"      </a>",
"      ) and in patients with severe malnutrition. They can also be seen in otherwise healthy people, who usually have fewer than three small lesions. As a general rule, the number and size of spider angiomata correlate with the severity of liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Patients with numerous and large spider angiomata may be at increased risk for variceal hemorrhage.",
"     </li>",
"     <li>",
"      Palmar erythema &mdash; Palmar erythema is an exaggeration of the normal speckled mottling of the palm, and is also believed to be caused by altered sex hormone metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/10\">",
"       10",
"      </a>",
"      ]. It is most frequently found on the thenar and hypothenar eminences while sparing the central portions of the palm. Palmar erythema is not specific for liver disease and can be seen in association with pregnancy rheumatoid arthritis, hyperthyroidism, and hematological malignancies.",
"     </li>",
"     <li>",
"      Nail changes &mdash; Muehrcke's nails are paired horizontal white bands separated by normal color. The exact pathogenesis is unknown but it is believed to be caused by hypoalbuminemia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/11\">",
"       11",
"      </a>",
"      ]. They are not specific for cirrhosis since they may also be seen in other conditions associated with a low serum albumin, such as the nephrotic syndrome.",
"      <br/>",
"      <br/>",
"      Terry's nails can also be seen in patients with cirrhosis. The proximal two-thirds of the nail plate appears white whereas the distal one-third is red. This finding is also believed to be secondary to a low serum albumin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clubbing and hypertrophic osteoarthropathy &mdash; Clubbing is present when the angle between the nail plate and proximal nail fold is greater than 180 degrees (",
"      <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"       figure 1",
"      </a>",
"      ). When severe, the distal finger has a drum stick appearance. Hypertrophic osteoarthropathy (HOA) is a chronic proliferative periostitis of the long bones that can cause considerable pain. Clubbing is more common in biliary causes of cirrhosis (particularly primary biliary cirrhosis) while hypertrophic osteoarthropathy can be seen with various causes of liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Neither feature is specific for liver disease.",
"      <br/>",
"      <br/>",
"      The pathogenesis of clubbing and hypertrophic osteoarthropathy are not well understood. The most frequent cause of HOA is lung cancer, which should be sought in the appropriate setting. Pathogenesis and disease associations are further discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"       \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dupuytren's contracture &mdash; Dupuytren's contracture results from the thickening and shortening of the palmar fascia, which causes flexion deformities of the fingers (",
"      <a class=\"graphic graphic_picture graphicRef70486 \" href=\"UTD.htm?35/58/36770\">",
"       picture 2",
"      </a>",
"      ). Pathologically, it is characterized by fibroblastic proliferation and disorderly collagen deposition with fascial thickening. The pathogenesis is unknown but may be related to free radical formation generated by the oxidative metabolism of hypoxanthine [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=see_link\">",
"       \"Dupuytren's contracture\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It is relatively common in patients with alcoholic cirrhosis in whom it may be found in as many as a third of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/15\">",
"       15",
"      </a>",
"      ]. However, it can also be seen in several other conditions including in workers exposed to repetitive handling tasks or vibration, and those with diabetes mellitus, reflex sympathetic dystrophy, cigarette smoking and alcohol consumption, and Peyronie's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=see_link\">",
"       \"Dupuytren's contracture\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gynecomastia &mdash; Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s). Fat deposition without glandular proliferation is termed pseudogynecomastia (often seen in obese men). These two entities can be distinguished by having the patient lie on his back with his hands behind his head. The examiner then places his or her thumb and forefinger on each side of the breast, and slowly brings them together (",
"      <a class=\"graphic graphic_figure graphicRef58568 \" href=\"UTD.htm?3/1/3095\">",
"       figure 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Up to two-thirds of patients with cirrhosis have gynecomastia. It is possibly caused by increased production of androstenedione from the adrenals, enhanced aromatization of androstenedione to estrone, and increased conversion of estrone to estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/16\">",
"       16",
"      </a>",
"      ]. Men may also develop other features reflecting feminization such as loss of chest or axillary hair and inversion of the normal male pubic hair pattern. Gynecomastia can be seen in a variety of conditions other than cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"       \"Epidemiology and pathogenesis of gynecomastia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"       \"Causes and evaluation of gynecomastia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testicular atrophy &mdash; Hypogonadism is manifested by impotence, infertility, loss of sexual drive, and testicular atrophy. It is a feature seen predominantly in patients with alcoholic cirrhosis and hemochromatosis. More than one mechanism appears to be involved. In some cases, primary gonadal injury appears to be more prominent, as suggested by increased serum FSH and LH concentrations, while in others suppression of hypothalamic or pituitary function appears to have a primary role, as suggested by serum LH concentrations that are not elevated. The toxic effects of alcohol or iron may also contribute to its development [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"       \"Causes of primary hypogonadism in males\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash; The cirrhotic liver may be enlarged, normal sized, or small. While the presence of a palpable liver may indicate liver disease, a non-palpable liver does not exclude it. When palpable, the cirrhotic liver has a firm and nodular consistency.",
"     </li>",
"     <li>",
"      Splenomegaly &mdash; Splenomegaly is common especially in patients with cirrhosis from nonalcoholic etiologies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/18\">",
"       18",
"      </a>",
"      ]. It is believed to be caused primarily by congestion of the red pulp as the result of portal hypertension. However, splenic size does not correlate well with portal pressures, suggesting that other factors may be contributing [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/10\">",
"       10",
"      </a>",
"      ]. The differential diagnosis of splenomegaly includes several other disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"       \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ascites &mdash; Ascites is the accumulation of fluid in the peritoneal cavity. The accuracy of physical findings is variable depending in part upon the amount of fluid present, the technique used to examine the patient, and the clinical setting (eg, detection may be more difficult in patients who are obese). In one study, the absence of flank dullness was the most accurate predictor against the presence of ascites; the probability of ascites being present was less than 10 percent in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/19\">",
"       19",
"      </a>",
"      ]. However, approximately 1500 mL of fluid had to be present for flank dullness to be detected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"       \"Evaluation of adults with ascites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Caput medusae &mdash; The veins of the lower abdominal wall normally drain inferiorly into the iliofemoral system while the veins of the upper abdominal wall drain superiorly into the veins of the thoracic wall and axilla. When portal hypertension occurs as the result of cirrhosis, the umbilical vein, normally obliterated in early life, may open. Blood from the portal venous system may be shunted through the periumbilical veins into the umbilical vein and ultimately to the abdominal wall veins, causing them to become prominent. This appearance has been said to resemble the head (caput) of the mythical Gorgon Medusa.",
"      <br/>",
"      <br/>",
"      Dilated abdominal veins can also be seen in the inferior vena cava syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/20\">",
"       20",
"      </a>",
"      ] and the superior vena cava syndrome (if obstruction includes the azygous system) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/21\">",
"       21",
"      </a>",
"      ]. In these conditions, collateral veins tend to be more prominent in the lateral aspect of the abdominal wall. One maneuver that has been proposed to distinguish vena caval obstruction from portal hypertension is to pass the finger along dilated veins located",
"      <strong>",
"       below",
"      </strong>",
"      the umbilicus to strip them of blood and determine the direction of blood flow during refilling. In portal-systemic collateral veins, the blood flow should be directed inferiorly away from the umbilicus in contrast to vena caval collateral vein flow in which the flow should be cephalad. However, the actual ability of this maneuver to discriminate between the two is poor since in both conditions the dilated veins may lack valves and thus have bidirectional blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cruveilhier-Baumgarten murmur &mdash; The Cruveilhier-Baumgarten murmur is a venous hum that may be auscultated in patients with portal hypertension. It results from collateral connections between the portal system and the remnant of the umbilical vein. It is best appreciated when the stethoscope is placed over the epigastrium. The murmur is augmented by maneuvers which increase intraabdominal pressure such as the Valsalva maneuver and diminished by applying pressure on the skin above the umbilicus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fetor hepaticus &mdash; A sweet, pungent smell to the breath of a patient with cirrhosis may occasionally be encountered. It is caused by increased concentrations of dimethylsulphide, the presence of which suggests underlying severe portal-systemic shunting [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Jaundice &mdash; Jaundice is a yellow coloring of the skin and mucus membranes that results from increased serum bilirubin. It is usually not detectable until the bilirubin is greater than 2 to 3",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      The hyperbilirubinemia may also cause the urine to appear dark or \"coca-cola\" colored. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"       \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Yellow discoloration to the skin can also be caused by excessive consumption of carotene (such as in patients who consume large quantities of carrots). Yellowing of the skin in carotenemia can be distinguished from jaundice by the absence of yellow discoloration in the sclera in the former.",
"     </li>",
"     <li>",
"      Asterixis &mdash; Asterixis (bilateral but asynchronous flapping motions of outstretched, dorsiflexed hands) is seen in patients with hepatic encephalopathy, which describes the spectrum of potentially reversible neuropsychiatric abnormalities seen in patients with liver dysfunction. Asterixis may also be seen in patients with uremia and severe heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; Patients with cirrhosis may also present with a diverse range of signs and symptoms that reflect the pivotal role that the liver has in the homeostasis of many different bodily functions. They may also have features suggesting the underlying cause of cirrhosis such as cryoglobulinemia from hepatitis C, diabetes mellitus and arthropathy in patients with hemochromatosis, and extrahepatic autoimmune diseases (such as hemolytic anemia or thyroiditis) in patients with autoimmune hepatitis. (See appropriate topic reviews.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other general features that may be seen include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constitutional symptoms such as weakness, fatigue, anorexia, and weight loss and features suggesting malnutrition.",
"     </li>",
"     <li>",
"      Pigment gallstones resulting from hemolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"       \"Epidemiology of and risk factors for gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parotid gland enlargement (probably due to alcohol, not cirrhosis per se). Enlargement is usually secondary to fatty infiltration, fibrosis, and edema rather than a hyperfunctioning gland [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diabetes mellitus is seen in 15 to 30 percent of patients with cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/27\">",
"       27",
"      </a>",
"      ]. It may be particularly common in patients with chronic hepatitis C. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\"",
"      </a>",
"      .) The pathogenesis is likely related to insulin resistance and an inadequate secretion of insulin from the beta cells of the pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/28\">",
"       28",
"      </a>",
"      ]. Diabetes may also be seen in patients with hemochromatosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2436017336\">",
"    <span class=\"h2\">",
"     Physical assessment for hepatomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the largest internal organ in humans and typically spans 21 to 23 cm horizontally and 14 to 17 cm vertically. The size of the normal liver varies depending upon sex, height, and body habitus.",
"   </p>",
"   <p>",
"    Physical examination of the liver can be helpful for assessing its shape and consistency or whether there is tenderness of the liver edge. It is less useful for assessing its size since assessment of liver size by physical examination correlates poorly with radiologic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/29\">",
"     29",
"    </a>",
"    ]. Nevertheless, the liver span can be estimated using percussion techniques or the scratch test. The scratch test uses auscultation while lightly scratching the skin. The intensity of the scratching sound increases when the liver is encountered with the scratching finger. A normal liver span in the mid-clavicular line by physical examination is 7 to 10 cm.",
"   </p>",
"   <p>",
"    In healthy people, the liver is generally not palpable because it lies posterior to the rib cage. By contrast, an enlarged liver can often be palpated below the costal margin. However, there are exceptions in which a normal-sized liver can be palpated below the costal margin including patients with emphysema, a thin-body habitus, the presence of a hypertrophied caudate lobe (such as seen in patients with Budd-Chiari syndrome), or Riedel's lobe (an anatomical variant in which there is an extension of the right-lobe downward and lateral toward the gallbladder).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cirrhosis is sometimes suggested by laboratory abnormalities. In today's medical practice, it is common for panels of serum chemistries to be sent for screening or evaluation of specific complaints. Although the term \"liver function tests\" (LFTs) is commonly used, it is imprecise since many of the tests reflecting the health of the liver are not direct measures of its function.",
"   </p>",
"   <p>",
"    The most common laboratory measures classified as LFTs include the enzyme tests (principally the serum aminotransferases, alkaline phosphatase, and gamma glutamyl transpeptidase), the serum bilirubin, and tests of synthetic function (principally the serum albumin concentration and prothrombin time).",
"   </p>",
"   <p>",
"    Certain abnormalities discovered on routine cell counts and chemistries can suggest the presence of advanced liver disease while providing clues to its severity and etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several noninvasive tests for diagnosis of cirrhosis have been proposed but none has yet emerged as a standard. Nevertheless, they can provide adjunctive information to conventional laboratory testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aminotransferases &mdash; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are usually moderately elevated. AST is more often elevated than ALT. However, normal aminotransferases do not preclude a diagnosis of cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/30\">",
"       30",
"      </a>",
"      ]. Most forms of chronic hepatitis other than alcohol have a ratio of",
"      <span class=\"nowrap\">",
"       AST/ALT",
"      </span>",
"      less than one. However, as chronic hepatitis progresses to cirrhosis, the ratio of AST to ALT may reverse [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link\">",
"       \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alkaline phosphatase &mdash; Alkaline phosphatase is usually elevated but less than two to three times the upper normal limit. Higher levels may be seen in patients with primary sclerosing cholangitis and primary biliary cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"       \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gamma-glutamyl transpeptidase &mdash; Gamma-glutamyl transpeptidase (GGT) levels correlate reasonably well with alkaline phosphatase in liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/33\">",
"       33",
"      </a>",
"      ]. Levels of GGT are typically much higher in chronic liver disease from alcohol than other causes. This may be the result of alcohol inducing hepatic microsomal GGT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/34\">",
"       34",
"      </a>",
"      ] or alcohol causing GGT to leak from hepatocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"       \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilirubin &mdash; Bilirubin levels may be normal in well compensated cirrhosis. However, they rise as the cirrhosis progresses. In patients with primary biliary cirrhosis, a rising serum bilirubin portends a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=see_link\">",
"       \"Clinical aspects of serum bilirubin determination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Albumin &mdash; Albumin is synthesized exclusively in the liver. Albumin levels fall as the synthetic function of the liver declines with worsening cirrhosis. Thus, serum albumin levels can be used to help grade the severity of cirrhosis. Hypoalbuminemia is not specific for liver disease since it may be seen in many other medical conditions such as congestive heart failure, the nephrotic syndrome, protein losing enteropathy, or malnutrition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"       \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prothrombin time &mdash; The liver is involved in the synthesis of many of the proteins required for normal clotting. Thus, the prothrombin time reflects the degree of hepatic synthetic dysfunction. The prothrombin time increases as the ability of a cirrhotic liver to synthesize clotting factors diminishes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"       \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Globulins &mdash; Globulins tend to be increased in patients with cirrhosis. This may be secondary to shunting of bacterial antigens in portal venous blood away from the liver to lymphoid tissue which induces immunoglobulin production [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/37\">",
"       37",
"      </a>",
"      ]. Marked elevations of IgG may be a clue to the presence of autoimmune hepatitis. Increased levels of IgM are present in 90 to 95 percent of patients with primary biliary cirrhosis.",
"     </li>",
"     <li>",
"      Serum sodium &mdash; Hyponatremia is common in patients with cirrhosis with ascites and is related to an inability to excrete free water. This results primarily from high levels of anti-diuretic hormone secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/38\">",
"       38",
"      </a>",
"      ]. Hyponatremia often becomes severe as cirrhosis progresses to end-stage liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"       \"Hyponatremia in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologic abnormalities &mdash; Patients with cirrhosis commonly have a number of hematologic abnormalities, including disorders of coagulation and varying degrees of cytopenia. Thrombocytopenia is the most common first hematologic abnormality while leukopenia and anemia develop later in the disease course [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is usually multifactorial in origin; acute and chronic gastrointestinal blood loss, folate deficiency, direct toxicity due to alcohol, hypersplenism, bone marrow suppression (as in hepatitis-associated aplastic anemia), the anemia of chronic disease (inflammation), and hemolysis may all contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is mainly caused by portal hypertension with attendant congestive splenomegaly. An enlarged spleen can result in temporary sequestration of up to 90 percent of the circulating platelet mass. However, this uncommonly results in platelet counts less than",
"    <span class=\"nowrap\">",
"     50,000/mL,",
"    </span>",
"    and, unless complicated by coexisting coagulopathy, is rarely a clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/33\">",
"     33",
"    </a>",
"    ]. Decreased thrombopoietin levels may also contribute to thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Leukopenia and neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia and neutropenia are due to hypersplenism with splenic margination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Coagulation defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the proteins involved in the coagulation process are produced in the liver. Thus, worsening coagulopathy correlates with the severity of hepatic dysfunction. In addition to deficiency of coagulant proteins, patients may develop varying degrees of DIC, fibrinolysis, vitamin K deficiency, dysfibrinogenemia, and thrombocytopenia, all of which may contribute to bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other liver function tests &mdash; The ability of the liver to transport organic anions and metabolize drugs has led to the development of a multitude of tests to assess the function of the liver. None is used routinely in clinical practice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=see_link\">",
"       \"Tests of the liver's capacity to transport organic anions and metabolize drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic markers &mdash; Serological markers of hepatic fibrosis are currently being examined to help predict the presence of cirrhosis without the need for liver biopsy. None is sufficiently accurate for routine clinical use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"       \"Noninvasive assessment of hepatic fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although radiographic findings can occasionally suggest the presence of cirrhosis, they are not adequately sensitive or specific for use as a primary diagnostic modality. The major utility of radiography in the evaluation of the cirrhotic patient is in its ability to detect complications of cirrhosis such as ascites, hepatocellular carcinoma, and hepatic or portal vein thrombosis. In rare instances, radiographic findings suggest the etiology of cirrhosis. A hypertrophied caudate lobe discovered on CT scanning, for example, suggests Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/41\">",
"     41",
"    </a>",
"    ]. Decreased signal intensity on MRI may indicate iron overload from hereditary hemochromatosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56593 \" href=\"UTD.htm?2/45/2769\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasonography &mdash; Ultrasonography is routinely used during the evaluation of the cirrhotic patient. It is noninvasive, well tolerated, widely available, and provides valuable information. In advanced cirrhosis, the liver may appear small and nodular. Surface nodularity and increased echogenicity with irregular appearing areas are consistent with cirrhosis but can also be seen with hepatic steatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. There is typically atrophy of the right lobe and hypertrophy of the caudate or left lobes. Investigators have attempted to use the ratio of the width of the caudate lobe to the width of the right lobe as an ultrasonographic criterion for the diagnosis of cirrhosis. However, the sensitivity is poor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Ultrasonography may be used as a screening test for hepatocellular carcinoma and portal hypertension. The finding of nodules on ultrasonography warrants further evaluation since benign and malignant nodules can have similar ultrasonographic appearance. Findings of portal hypertension include an increased diameter of the portal vein and the presence of collateral veins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/46\">",
"       46",
"      </a>",
"      ]. Ultrasonography is also useful for detecting splenomegaly, ascites, and portal vein thrombosis. (See appropriate topic reviews.)",
"     </li>",
"     <li>",
"      \"Stiffness\" measurement &mdash; Increasing scarring of the liver is associated with increasing \"stiffness\" of the tissue. A sonographic technique to assess liver stiffness has been developed (Fibroscan, EchoSens, Paris, France). A vibration of mild amplitude and low frequency is transmitted through the liver inducing an elastic shear wave that propagates through the tissue. A pulse-echo ultrasound follows the propagation of the wave; the harder the tissue (and hence the more dense the fibrosis) the faster the wave propagates. Initial assessment of the device suggests that it has excellent test characteristics in patients with advanced fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"       \"Noninvasive assessment of hepatic fibrosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The test is limited in patients with obesity, narrow intercostal spaces, and ascites. Further validation studies are needed to clarify its role. The device is not commercially available in the United States.",
"     </li>",
"     <li>",
"      Computed tomography &mdash; Computed tomography is not routinely used in the diagnosis and evaluation of cirrhosis. It provides similar information to ultrasonography, but at the expense of radiation and contrast exposure. CT findings may suggest the presence of cirrhosis, but they are not diagnostic.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging &mdash; The role of magnetic resonance imaging (MRI) in the diagnosis of cirrhosis is unclear. Despite much enthusiasm about the potential of MRI in the evaluation of the cirrhotic patient, its use today is limited by expense, patient intolerability, and the ability to obtain information provided by MRI through other means.",
"      <br/>",
"      <br/>",
"      Some authors report that MRI can accurately diagnose cirrhosis and provide correlation with its severity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. One study found the sensitivity and specificity of an MRI scoring system in distinguishing Child-Pugh grade A cirrhosis from other grades to be 93 and 82 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/47\">",
"       47",
"      </a>",
"      ]. MRI may also reveal iron overload and provide an estimate of the hepatic iron concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/42,50,51\">",
"       42,50,51",
"      </a>",
"      ]. MR angiography is more sensitive than ultrasonography in diagnosing complications of cirrhosis such as portal vein thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nuclear studies &mdash; Radionuclide testing can be useful in suggesting the diagnosis of cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/53\">",
"       53",
"      </a>",
"      ]. 99mTc sulfur colloid is normally taken up by cells of the reticuloendothelial system. In patients with cirrhosis, there may be heterogeneity in the uptake of 99mTc sulfur colloid by the liver and increased uptake by the spleen and bone marrow. The exact sensitivity and specificity of these findings in making the diagnosis of cirrhosis is unknown. Given the widespread use of the other imaging modalities discussed above, this test is seldom performed in clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONFIRMING THAT THE PATIENT HAS CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for diagnosis of cirrhosis is examination of an explanted liver at autopsy or following liver transplantation during which the architecture of the entire liver can be appreciated. In clinical practice, cirrhosis is diagnosed with a liver biopsy during which a sample of the liver is obtained by either a percutaneous, transjugular, laparoscopic, or radiographically-guided fine-needle approach depending upon the clinical setting (",
"    <a class=\"graphic graphic_picture graphicRef76262 \" href=\"UTD.htm?37/47/38643\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/54\">",
"     54",
"    </a>",
"    ]. Serologic and radiographic methods to diagnose cirrhosis continue to be studied but none has yet supplanted liver histology as the gold standard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of a liver biopsy for cirrhosis is in the range of 80 to 100 percent depending upon the method used, and the size and number of specimens obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=see_link\">",
"     \"Transjugular liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, liver biopsy is not necessary if the clinical, laboratory, and radiologic data strongly suggest the presence of cirrhosis. An example would be a patient with ascites, severe coagulopathy, and a shrunken nodular appearing liver on ultrasonography.",
"   </p>",
"   <p>",
"    In addition to demonstrating that cirrhosis is present, a liver biopsy can sometimes suggest the cause. This is especially true for metabolic causes of cirrhosis such as hereditary hemochromatosis (",
"    <a class=\"graphic graphic_picture graphicRef50096 \" href=\"UTD.htm?3/53/3927\">",
"     picture 4",
"    </a>",
"    ), NASH (",
"    <a class=\"graphic graphic_picture graphicRef51497 \" href=\"UTD.htm?6/57/7059\">",
"     picture 5",
"    </a>",
"    ), Wilson's disease, and alpha-1 antitrypsin deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DETERMINING THE CAUSE OF CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many causes of chronic liver injury can lead to cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef55647 \" href=\"UTD.htm?29/63/30716\">",
"     table 1",
"    </a>",
"    ), a specific etiology can usually be determined by the history combined with serologic and histologic evaluation. The two most common causes in the United States are alcoholic liver disease and hepatitis C, which together account for almost one-half of those undergoing transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proportion of patients with cirrhosis without an apparent cause (cryptogenic cirrhosis) is declining. In 1960, nearly a third of all cases of cirrhosis were considered cryptogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/55\">",
"     55",
"    </a>",
"    ] compared to 10 to 15 percent today [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/56\">",
"     56",
"    </a>",
"    ]. The proportion may be declining further since it is becoming increasingly apparent that many such patients may actually have had unrecognized nonalcoholic steatohepatitis (NASH) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determination of the etiology of cirrhosis is important since it may influence treatment decisions, counseling of family members, and help predict complications. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cirrhosis related to autoimmune hepatitis may have clinical and histologic improvement (including regression of fibrosis) when treated with corticosteroids justifying the use of corticosteroids even in those with advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phlebotomy decreases complications of portal hypertension in patients with cirrhosis who have hereditary hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"       \"Treatment of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic measures (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      ) are required in patients undergoing transplantation for cirrhosis related to hepatitis B. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"       \"Liver transplantation for chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family members of patients diagnosed with hemochromatosis or Wilson's disease may require genetic counseling and screening. Appropriate preventive measures and advice can be discussed with family members of patients with chronic viral hepatitis or alcoholic cirrhosis. (See appropriate topic reviews.)",
"     </li>",
"     <li>",
"      The risk for hepatocellular carcinoma is higher in patients with cirrhosis from viral hepatitis or hemochromatosis compared to patients with autoimmune hepatitis or NASH [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Morphologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis was historically classified morphologically as micronodular, macronodular, or mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/63\">",
"     63",
"    </a>",
"    ]. Micronodular cirrhosis, characterized by nodules less than 3 mm in diameter, was believed to be caused by alcohol, hemochromatosis, cholestatic causes of cirrhosis, and hepatic venous outflow obstruction. Macronodular cirrhosis, characterized by various sized nodules larger than 3 mm, was believed to be secondary to chronic viral hepatitis.",
"   </p>",
"   <p>",
"    Although important from a historical perspective, the morphological classification system has a number of limitations and has thus largely been abandoned. First, it is relatively nonspecific with regard to etiology. Second, the morphologic appearance of the liver may change as the liver disease progresses; micronodular cirrhosis usually progresses to macronodular cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/64\">",
"     64",
"    </a>",
"    ]. Third, serological markers available today are more specific than morphological appearance of the liver for determining the etiology of cirrhosis. As an example, antimitochondrial antibodies have a specificity of 98 percent for primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/65\">",
"     65",
"    </a>",
"    ]. Finally, accurate assessment of liver morphology can only be achieved at surgery, laparoscopy, or autopsy, while in today's clinical practice there are less invasive means to make an etiologic diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Testing for specific diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The order and selection of specific tests for determining the cause of cirrhosis should be guided by the available information from the history, physical examination, and laboratory and radiologic tests, which may point toward a diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic liver disease &mdash; Documenting chronic alcohol abuse is the most important aspect of diagnosing alcoholic liver disease, although it is often denied by the patient. Patients with concurrent alcoholic hepatitis may present with fever, hepatomegaly, jaundice, and anorexia. Alcoholic hepatitis is also associated with the classical laboratory findings of a disproportionate elevation of AST (aspartate aminotransferase, SGOT) compared to ALT (alanine aminotransferase, SGPT), with both values usually being less than 300",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      This ratio is generally greater than 2.0, a value that is rarely seen in other forms of liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Liver biopsy, if performed, may reveal the typical findings of alcoholic hepatitis, including liver cell necrosis, Mallory bodies, infiltration by neutrophils, and a perivenular distribution of inflammation (",
"      <a class=\"graphic graphic_picture graphicRef75188 \" href=\"UTD.htm?33/52/34628\">",
"       picture 6",
"      </a>",
"      ). Alcoholic fibrosis, like the hepatitis lesion, first appears in the pericentral zone and then progresses to panlobular fibrosis in those who continue to drink. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic hepatitis C virus infection &mdash; The diagnostic tests for hepatitis C virus (HCV) infection consist of serologic assays that detect antibody to hepatitis C and molecular assays that detect or quantify HCV RNA. A liver biopsy can be helpful for establishing the severity of disease and evaluating for contributing causes such as alcohol (",
"      <a class=\"graphic graphic_picture graphicRef55740 \" href=\"UTD.htm?29/26/30119\">",
"       picture 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic hepatitis B virus infection &mdash; Chronic hepatitis B virus (HBV) infection is a much less common cause of cirrhosis than hepatitis C in the United States. The diagnosis of chronic HBV infection is based upon the detection of HBsAg more than four to six months after initial infection. Additional tests for HBV replication &mdash; HBeAg and serum HBV DNA&mdash; should be performed to determine if the patient should be considered for antiviral therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"       \"Serologic diagnosis of hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonalcoholic steatohepatitis &mdash; Nonalcoholic steatohepatitis (NASH) is a disorder diagnosed by liver biopsy. The biopsy findings are indistinguishable from those of alcoholic hepatitis described above but the patient lacks a history of significant alcohol consumption. The liver disease is stable in most patients but a minority progress to cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis &mdash; Patients with primary biliary cirrhosis (PBC) may be asymptomatic or present with a history of fatigue, pruritus, and skin hyperpigmentation that is not due to jaundice. The physical examination typically reveals hepatomegaly and less often splenomegaly. Laboratory tests reveal pronounced elevations in the serum alkaline phosphatase concentration, which is of hepatic origin; affected patients may also have striking elevations in the serum cholesterol concentration while hyperbilirubinemia is not seen until late in the course of the disease. Modest elevations in serum bilirubin that persists for more than three to six months imply a poor prognosis; such patients should be referred for liver transplantation even in the absence of life-threatening complications related to cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Antimitochondrial antibodies are the serologic hallmark of PBC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5737?source=see_link\">",
"       \"Pathogenesis of primary biliary cirrhosis\"",
"      </a>",
"      .) The ELISA tests are 95 percent sensitive and 98 percent specific for PBC. Liver biopsy is usually confirmatory rather than diagnostic. The pathognomonic florid bile duct lesion is uncommonly seen in percutaneous needle biopsies of the liver (",
"      <a class=\"graphic graphic_picture graphicRef54128 graphicRef66904 \" href=\"UTD.htm?32/43/33466\">",
"       picture 8A-B",
"      </a>",
"      ). The continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance.",
"      <br/>",
"      <br/>",
"      Imaging tests or cholangiography are not needed in most patients. Endoscopic retrograde cholangiography is typically normal or shows narrow caliber bile ducts in PBC, and is helpful in the patient in whom the antimitochondrial antibody test is negative and the possibility of primary sclerosing cholangitis or a carcinoma of the bile duct or pancreas exists.",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis &mdash; Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of the liver and bile ducts that is frequently progressive. The clinical presentation is that of a cholestatic liver disease, including pruritus, steatorrhea, fat soluble vitamin deficiencies, and metabolic bone disease. Complications are common, including dominant biliary strictures, cholangitis, cholelithiasis, cholangiocarcinoma, and colon cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is a strong association between PSC and inflammatory bowel disease, particularly ulcerative colitis (UC) but also Crohn's disease. The incidence of UC in patients approaches 90 percent when rectal and sigmoid biopsies are routinely obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link\">",
"       \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The diagnosis is best established by contrast cholangiography, which reveals a characteristic picture of diffuse, multifocal strictures and focal dilation of the bile ducts, leading to a beaded appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72605 \" href=\"UTD.htm?21/6/21615\">",
"       image 2",
"      </a>",
"      ). The term \"primary\" is used to distinguish PSC from other conditions that may lead to a similar clinical and cholangiographic syndrome. These include choledocholithiasis, cholangiocarcinoma, bacterial cholangitis, prior biliary surgery, intraarterial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"       floxuridine",
"      </a>",
"      , and acquired immunodeficiency syndrome associated cholangiopathy.",
"      <br/>",
"      <br/>",
"      PSC is also associated with a number of immunologic abnormalities, none of which is diagnostic. These include an elevated serum IgM concentration in 50 percent and several autoantibodies. The most common are anti-smooth muscle and antinuclear antibodies, and antibodies directed against cytoplasmic and nuclear antigens of neutrophils. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link\">",
"       \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune hepatitis &mdash; Establishing the diagnosis of autoimmune hepatitis is particularly important because therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      is beneficial. Many patients, even those with established cirrhosis, respond when treatment is initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A characteristic laboratory feature of autoimmune hepatitis, although not universally present, is an elevation in serum globulins, particularly gamma globulins. This hyperglobulinemia is generally associated with circulating autoantibodies, which are particularly helpful in identifying autoimmune hepatitis. There are two major types of autoimmune hepatitis which are characterized by specific autoantibodies: antinuclear, anti-smooth muscle, antiactin antibodies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ANCA in type 1; and anti-LKM-1 and anti-ALC-1 (anti-liver cytosol) antibodies in type 2 (",
"      <a class=\"graphic graphic_table graphicRef65135 \" href=\"UTD.htm?8/0/8203\">",
"       table 2",
"      </a>",
"      ). On occasion, antimitochondrial antibodies occur in association with antinuclear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      smooth muscle antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The diagnosis of autoimmune hepatitis can be difficult to establish because the characteristic autoantibodies may be present and the liver biopsy reveals characteristic but nonspecific changes such as a portal mononuclear cell infiltrate which invades the sharply demarcated hepatocyte boundary (limiting plate) surrounding the portal triad; plasma cells are often seen in the inflammatory infiltrate (",
"      <a class=\"graphic graphic_picture graphicRef67909 \" href=\"UTD.htm?7/41/7830\">",
"       picture 9",
"      </a>",
"      ). Given the possible difficulties in diagnosis, some clinicians will initiate a trial of corticosteroids in patients with a compatible picture and no other apparent cause of cirrhosis, particularly if the serum aminotransferases are elevated and prominent hyperglobulinemia is present.",
"     </li>",
"     <li>",
"      Hereditary hemochromatosis &mdash; The presence of hereditary hemochromatosis (HH) may be suspected if there is a family history of cirrhosis or if the patient also has skin hyperpigmentation, diabetes mellitus, pseudogout,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Signs of iron overload are also typically present in HH. A fasting transferrin saturation of &ge;60 percent in men and &ge;50 percent in women will detect about 90 percent of patients with homozygous HH. However, many investigators have advocated using a \"cutoff\" value of 45 percent for both men and women, which will lead to fewer patients being missed (at the expense of leading to the identification of more false positives).",
"      <br/>",
"      <br/>",
"      Increased iron also stimulates the hepatic production and release of ferritin. As a result, a plasma ferritin concentration above 300",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in men and 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in women provides further support for the diagnosis of iron overload. An elevated plasma ferritin is generally less sensitive than the transferrin saturation in screening for HH because a greater degree of iron overload is required to raise the ferritin concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/41/23194/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, an elevation in the plasma ferritin and increased iron saturation can also be seen in patients with a variety of liver diseases. Thus, other tests are required to confirm the diagnosis in patients who present with cirrhosis. This can be achieved in one of three ways: genetic testing, which is now available; liver biopsy; and the response to quantitative phlebotomy. In the absence of genetic testing, liver biopsy is usually required to confirm the diagnosis of homozygous HH; heterozygotes do not develop cirrhosis in the absence of some other type of liver disease (eg, viral hepatitis, nonalcoholic steatohepatitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Parenchymal iron loading can be demonstrated by Perls' Prussian blue staining of a liver biopsy, and fibrosis can be detected if it exists (",
"      <a class=\"graphic graphic_picture graphicRef50096 \" href=\"UTD.htm?3/53/3927\">",
"       picture 4",
"      </a>",
"      ). The hepatic tissue can also be directly analyzed for iron content which must be performed meticulously to detect nonheme iron. The hepatic iron content is preferably reported as micromoles of iron per gram dry weight of liver. Normal values are less than 36",
"      <span class=\"nowrap\">",
"       &micro;mol/g,",
"      </span>",
"      while values above 71",
"      <span class=\"nowrap\">",
"       &micro;mol/g",
"      </span>",
"      are highly suggestive of homozygous HH. This value can be divided by the subject's age in years to give the hepatic iron index (HII); a value &ge;1.9 is also highly suggestive of homozygous HH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=see_link\">",
"       \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"      </a>",
"      .) If either of these test results is increased, genetic testing for this disorder is warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"       \"Genetics of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; Other causes of cirrhosis are much less common but should be considered in the appropriate clinical setting. As an example, Wilson's disease is an autosomal recessive disorder which should be suspected in any patient who has a personal or family history of cirrhosis at a young age or who presents with fulminant hepatic failure under the age of 45. The diagnosis is usually established by the findings of a low serum ceruloplasmin concentration (present in 95 percent of patients) and increased hepatic copper content on liver biopsy, a finding that can also be seen in cholestatic liver diseases such as primary biliary cirrhosis and primary sclerosing cholangitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"       \"Tests used in the diagnosis of Wilson disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Alpha-1 antitrypsin (AAT) deficiency is also an autosomal recessive disorder which can cause cirrhosis in children and in 10 to 15 percent of adults who may also have chronic obstructive pulmonary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"       \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .) The first step in an individual suspected of having AAT deficiency is measurement of serum AAT concentrations. Phenotyping should be saved for individuals who have a low or borderline AAT concentration; this test requires skill and experience, so care should be taken to select a laboratory that can provide these features.",
"      <br/>",
"      <br/>",
"      Longstanding right-sided heart failure and resulting hepatic congestion can lead to the development of cirrhosis (sometimes referred to as \"cardiac cirrhosis\"). The diagnosis should be suspected in the appropriate clinical setting when other causes of liver disease have been excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link\">",
"       \"Congestive hepatopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       \"Patient information: Cirrhosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       \"Patient information: Cirrhosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cirrhosis may present in a variety of ways and with varied clinical findings. The history and physical examination can provide clues as to the presence of cirrhosis and suggest an etiology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine laboratory tests are generally not diagnostic but can suggest the presence of liver disease. In advanced stages there may be an elevated prothrombin time and total bilirubin, and a reduced platelet count and serum albumin. We suggest obtaining, at a minimum, a complete blood count and differential, total bilirubin, albumin, and serum aminotransferase levels. Additional testing may be warranted when specific forms of liver disease are suspected (see below).",
"     </li>",
"     <li>",
"      Radiographic findings can occasionally suggest the presence of cirrhosis but are not adequately sensitive or specific for use as a primary diagnostic modality. The major utility of radiography in the evaluation of patients with cirrhosis is in its ability to detect complications of cirrhosis such as ascites, hepatocellular carcinoma, and hepatic or portal vein thrombosis. In rare instances, radiographic findings suggest the etiology of cirrhosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cirrhosis has traditionally been confirmed with a liver biopsy during which a sample of the liver is obtained by either a percutaneous, transjugular, laparoscopic, or radiographically-guided fine-needle approach depending upon the clinical setting. The sensitivity of a liver biopsy for cirrhosis is in the range of 80 to 100 percent depending upon the method used, and the size and number of specimens obtained. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Confirming that the patient has cirrhosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several noninvasive tests for diagnosis of cirrhosis have been proposed but none has yet emerged as a standard. Nevertheless, they can provide adjunctive information to conventional laboratory testing and in some settings may replace a liver biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"       \"Noninvasive assessment of hepatic fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is important to establish the cause of cirrhosis since it has a bearing on treatment and prognosis. The order and selection of specific tests for determining the cause of cirrhosis should be guided by the available information from the history, physical examination, and laboratory and radiologic tests, which may point toward a diagnosis.",
"      <br/>",
"      <br/>",
"      Commonly used panels of serologic screening tests include assessment for chronic hepatitis B and C (HBsAg, HBsAb, HCV ab), autoimmune hepatitis (antinuclear and anti-smooth muscle antibodies), hemochromatosis (Fe, ferritin and total iron binding capacity), primary biliary cirrhosis (antimitochondrial antibodies), and Wilson's disease (serum ceruloplasmin). We commonly obtain a right upper quadrant ultrasound to assess for features suggestive of liver disease and to exclude biliary obstruction. As noted above, a liver biopsy remains the reference standard for establishing the presence of cirrhosis and can also help uncover its cause. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Testing for specific diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/1\">",
"      Runyon BA. A Primer on Detecting Cirrhosis and Caring for These Patients without Causing Harm. Int J Hepatol 2011; 2011:801983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/2\">",
"      HAELLEN J, NORDEN J. LIVER CIRRHOSIS UNSUSPECTED DURING LIFE. A SERIES OF 79 CASES. J Chronic Dis 1964; 17:951.",
"     </a>",
"    </li>",
"    <li>",
"     Conn H, Atterbury C. Cirrhosis. In: Diseases of the Liver, 7th edition, Schiff L, Schiff E (Eds), Lippencott Company, Philadelphia 1993. p.875.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/4\">",
"      Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver disease have cirrhosis? JAMA 2012; 307:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/5\">",
"      Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/6\">",
"      Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/7\">",
"      Pirovino M, Linder R, Boss C, et al. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr 1988; 66:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/8\">",
"      Zaman A, Hapke R, Flora K, et al. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999; 94:3292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/9\">",
"      Foutch PG, Sullivan JA, Gaines JA, Sanowski RA. Cutaneous vascular spiders in cirrhotic patients: correlation with hemorrhage from esophageal varices. Am J Gastroenterol 1988; 83:723.",
"     </a>",
"    </li>",
"    <li>",
"     Erlinger S, Benhamou J. Cirrhosis: Clinical aspects. In: Oxford Textbook of Clinical Hepatology, Mcintyre N, Benhamou J, Rizzetto M, et al (Eds), University Press, Oxford 1991. p.380.",
"    </li>",
"    <li>",
"     Fitzpatrick T, Johnson R, Polano M, et al. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, Second edition, McGraw Hill, Inc, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/12\">",
"      Mills PR, Vallance R, Birnie G, et al. A prospective survey of radiological bone and joint changes in primary biliary cirrhosis. Clin Radiol 1981; 32:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/13\">",
"      Epstein O, Dick R, Sherlock S. Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease. Gut 1981; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/14\">",
"      Murrell GA, Francis MJ, Bromley L. Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 1987; 295:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/15\">",
"      Attali P, Ink O, Pelletier G, et al. Dupuytren's contracture, alcohol consumption, and chronic liver disease. Arch Intern Med 1987; 147:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/16\">",
"      Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis 1985; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/17\">",
"      van Thiel DH, Gavaler JS, Spero JA, et al. Patterns of hypothalamic-pituitary-gonadal dysfunction in men with liver disease due to differing etiologies. Hepatology 1981; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/18\">",
"      Soper NJ, Rikkers LF. Effect of operations for variceal hemorrhage on hypersplenism. Am J Surg 1982; 144:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/19\">",
"      Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982; 247:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/20\">",
"      MISSAL ME, ROBINSON JA, TATUM RW. INFERIOR VENA CAVA OBSTRUCTION: CLINICAL MANIFESTATIONS, DIAGNOSTIC METHODS, AND RELATED PROBLEMS. Ann Intern Med 1965; 62:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/21\">",
"      Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. Curr Probl Cancer 1986; 10:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/22\">",
"      Coetzee T. Clinical anatomy of the umbilicus. S Afr Med J 1980; 57:463.",
"     </a>",
"    </li>",
"    <li>",
"     Groszmann R, Franchis R. Portal Hypertension. In: Diseases of the Liver, Eighth Edition, Schiff E, Sorrell M, Maddrey W (Eds), Lippincott Williams &amp; Wilkens, Philadelphia 1999. p.415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/24\">",
"      Tangerman A, Meuwese-Arends MT, Jansen JB. Cause and composition of foetor hepaticus. Lancet 1994; 343:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/25\">",
"      Bouchier IA. Postmortem study of the frequency of gallstones in patients with cirrhosis of the liver. Gut 1969; 10:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/26\">",
"      Dutta SK, Dukehart M, Narang A, Latham PS. Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology 1989; 96:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/27\">",
"      Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/28\">",
"      Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/29\">",
"      Niederau C, Sonnenberg A, M&uuml;ller JE, et al. Sonographic measurements of the normal liver, spleen, pancreas, and portal vein. Radiology 1983; 149:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/30\">",
"      Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/31\">",
"      Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/32\">",
"      Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734.",
"     </a>",
"    </li>",
"    <li>",
"     Pratt D, Kaplan M. Evaluation of the Liver A: Laboratory Tests. In: Schiff's Diseases of the Liver, Eighth Edition, Schiff E, Sorrell M, Maddrey W (Eds), Lippincott Williams &amp; Wilkens, Philadelphia 1999. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/34\">",
"      Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/35\">",
"      Barouki R, Chobert MN, Finidori J, et al. Ethanol effects in a rat hepatoma cell line: induction of gamma-glutamyltransferase. Hepatology 1983; 3:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/36\">",
"      Krzeski P, Zych W, Kraszewska E, et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999; 30:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/37\">",
"      Triger DR, Wright R. Hyperglobulinaemia in liver disease. Lancet 1973; 1:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/38\">",
"      Asbert M, Gin&egrave;s A, Gin&egrave;s P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/39\">",
"      Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/40\">",
"      Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009; 7:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/41\">",
"      Becker CD, Scheidegger J, Marincek B. Hepatic vein occlusion: morphologic features on computed tomography and ultrasonography. Gastrointest Radiol 1986; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/42\">",
"      Ernst O, Sergent G, Bonvarlet P, et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol 1997; 168:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/43\">",
"      Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/44\">",
"      Sanford NL, Walsh P, Matis C, et al. Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology 1985; 89:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/45\">",
"      Giorgio A, Amoroso P, Lettieri G, et al. Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology 1986; 161:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/46\">",
"      Zwiebel WJ. Sonographic diagnosis of hepatic vascular disorders. Semin Ultrasound CT MR 1995; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/47\">",
"      Ito K, Mitchell DG, Hann HW, et al. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol 1999; 173:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/48\">",
"      Ito K, Mitchell DG, Gabata T, Hussain SM. Expanded gallbladder fossa: simple MR imaging sign of cirrhosis. Radiology 1999; 211:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/49\">",
"      Ito K, Mitchell DG, Hann HW, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/50\">",
"      Bonkovsky HL, Rubin RB, Cable EE, et al. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999; 212:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/51\">",
"      Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/52\">",
"      Finn JP, Kane RA, Edelman RR, et al. Imaging of the portal venous system in patients with cirrhosis: MR angiography vs duplex Doppler sonography. AJR Am J Roentgenol 1993; 161:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/53\">",
"      McLaren MI, Fleming JS, Walmsley BH, et al. Dynamic liver scanning in cirrhosis. Br J Surg 1985; 72:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/54\">",
"      Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/55\">",
"      SUMMERSKILL WH, DAVIDSON CS, DIBLE JH, et al. Cirrhosis of the liver: a study of alcoholic and nonalcoholic patients in Boston and London. N Engl J Med 1960; 262:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/56\">",
"      Charlton MR, Kondo M, Roberts SK, et al. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/57\">",
"      Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/58\">",
"      Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/59\">",
"      Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/60\">",
"      Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/61\">",
"      Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995; 22:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/62\">",
"      Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/63\">",
"      Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/64\">",
"      Fauerholdt L, Schlichting P, Christensen E, et al. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology 1983; 3:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/41/23194/abstract/65\">",
"      Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1253 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-97BC8CC2DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23194=[""].join("\n");
var outline_f22_41_23194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2436017336\">",
"      Physical assessment for hepatomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Leukopenia and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Coagulation defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONFIRMING THAT THE PATIENT HAS CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DETERMINING THE CAUSE OF CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Morphologic classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Testing for specific diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1253|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/45/2769\" title=\"diagnostic image 1\">",
"      Hemochromatosis MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/6/21615\" title=\"diagnostic image 2\">",
"      Intrahepatic PSC ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1253|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 1\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/1/3095\" title=\"figure 2\">",
"      Examination for gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1253|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/23/369\" title=\"picture 1\">",
"      Spider angiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/58/36770\" title=\"picture 2\">",
"      Dupuytrens contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/47/38643\" title=\"picture 3\">",
"      Cirrhosis trichrome Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/53/3927\" title=\"picture 4\">",
"      Iron overload liver Perls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/57/7059\" title=\"picture 5\">",
"      NASH Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/52/34628\" title=\"picture 6\">",
"      Mallory body alcohol hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/26/30119\" title=\"picture 7\">",
"      ETOH and HCV Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/48/12040\" title=\"picture 8A\">",
"      Primary biliary cirrhosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27911\" title=\"picture 8B\">",
"      Primary biliary cirrhosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7830\" title=\"picture 9\">",
"      Autoimmune hepatitis Low",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1253|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/63/30716\" title=\"table 1\">",
"      Evaluation of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/0/8203\" title=\"table 2\">",
"      Classif autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=related_link\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5737?source=related_link\">",
"      Pathogenesis of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=related_link\">",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=related_link\">",
"      Transjugular liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_41_23195="Osmoregulation v volume reg";
var content_f22_41_23195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences between osmoregulation and volume regulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osmoregulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What is being sensed",
"       </td>",
"       <td>",
"        Plasma osmolality",
"       </td>",
"       <td>",
"        Effective circulating volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Sensors",
"       </td>",
"       <td rowspan=\"3\">",
"        Hypothalamic osmoreceptors",
"       </td>",
"       <td>",
"        Carotic sinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Afferent glomerular arteriole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Effectors",
"       </td>",
"       <td rowspan=\"5\">",
"        Antidiuretic hormone",
"       </td>",
"       <td>",
"        Sympathetic nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renin-angiotensin-aldosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natriuretic peptides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure natriuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidiuretic hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        What is affected",
"       </td>",
"       <td>",
"        Water excretion (via ADH)",
"       </td>",
"       <td rowspan=\"2\">",
"        Sodium excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water intake (via thirst)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23195=[""].join("\n");
var outline_f22_41_23195=null;
var title_f22_41_23196="Fast v slow conduction";
var content_f22_41_23196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fast versus slow response cardiac tissues",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Properties",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fast response times",
"       </td>",
"       <td class=\"subtitle1\">",
"        Slow response times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Location",
"       </td>",
"       <td>",
"        Atria, specialized infranodal conducting system, ventricles, AV bypass tracts",
"       </td>",
"       <td>",
"        Sinoatrial and atrioventricular nodes, depolarized fast response tissues in which phase 0 depends upon calcium current",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Passive cellular properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal resting potential",
"       </td>",
"       <td>",
"        -80 to -95 mV",
"       </td>",
"       <td>",
"        -40 to -65 mV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Active cellular properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phase 0 current",
"       </td>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        Primarily calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phase 0 channel kinetics",
"       </td>",
"       <td>",
"        Fast",
"       </td>",
"       <td>",
"        Slow activation; inactivation depends upon voltage and cell calcium concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peak overshoot",
"       </td>",
"       <td>",
"        +20 to +40 mV",
"       </td>",
"       <td>",
"        -5 to + 20 mV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Action potential amplitude",
"       </td>",
"       <td>",
"        90 to 135 mV",
"       </td>",
"       <td>",
"        30 to 70 mV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Properties dependent upon active and passive properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Threshold voltage",
"       </td>",
"       <td>",
"        -60 to -75 mV",
"       </td>",
"       <td>",
"        -40 to -60 mV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduction velocity",
"       </td>",
"       <td>",
"        0.5 to 5 m/sec",
"       </td>",
"       <td>",
"        0.01 to 0.1 m/sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conducive to reentry",
"       </td>",
"       <td>",
"        Only with inactivation of sodium channels with marked slowing of conduction velocity",
"       </td>",
"       <td>",
"        Present in normal tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Automaticity",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of the major electrophysiologic characteristics of \"fast\" and \"slow\" response tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23196=[""].join("\n");
var outline_f22_41_23196=null;
var title_f22_41_23197="Contents: Soft tissue rheumatism";
var content_f22_41_23197=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Soft tissue rheumatism",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Soft tissue rheumatism",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27016\">",
"           Popliteal (Baker's) cyst",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-1B97CC167B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_41_23197=[""].join("\n");
var outline_f22_41_23197=null;
var title_f22_41_23198="Hood silicone stent";
var content_f22_41_23198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hood silicone stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smooth-walled silicone Hood tracheobronchial stent with Y configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23198=[""].join("\n");
var outline_f22_41_23198=null;
var title_f22_41_23199="Magnets as nasal foreign bodies";
var content_f22_41_23199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Magnets as nasal foreign bodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 13 year old boy&nbsp;placed flashing-light magnetic-backed earrings on both alae. The magnets subsequently attached across the nasal septum high in the anterior nasal cavity. One battery is visualized here (dotted box).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Starke L. Easy removal of nasal magnets. Pediatr Emerg Care 2005; 21:598. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_41_23199=[""].join("\n");
var outline_f22_41_23199=null;
